



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/715	A2	(11) International Publication Number: WO 96/40168 (43) International Publication Date: 19 December 1996 (19.12.96)
(21) International Application Number: PCT/US96/08098 (22) International Filing Date: 31 May 1996 (31.05.96) (30) Priority Data: 08/482,235 7 June 1995 (07.06.95) US (71) Applicant: UNIVERSITY OF SOUTHERN CALIFORNIA [US/US]; University Park Campus, Los Angeles, CA 90089 (US). (72) Inventor: DIZEREGA, Gere, Stodder, 1270 Hillcrest Avenue, Pasadena, CA 91105 (US). (74) Agent: MIAO, Emily; Banner & Allegretti, Ltd., Ten South Wacker Drive, Chicago, IL 60606 (US).		(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: USE OF HYDROXYETHYL STARCH TO PREVENT POST SURGICAL ADHESION AND AS AN INTRACAVITY CARRIER DEVICE (57) Abstract Hydroxyethyl starch (HES) and use thereof in methods are provided for reducing or preventing adhesion formation between tissue surfaces, e.g., organ surfaces, in body cavities following surgical procedures and for drug delivery. HES may be used as an absorbable mechanical barrier alone or in combination with one or more anti-adhesion formation compounds for application to injured areas of tissues, e.g., organs, situated in body cavities such as the peritoneal, pelvic, pleural cavity, central nervous system and interligamentous space. HES may also be used as an intracavity carrier device for delivery of pharmaceutically active agents.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Larvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

USE OF HYDROXYETHYL STARCH TO PREVENT POST SURGICAL ADHESION AND AS AN
INTRACAVITY CARRIER DEVICE

FIELD OF THE INVENTION

5 The present invention relates to hydroxyethyl starch
and use thereof as an absorbable mechanical barrier for
minimizing or preventing post-operative adhesion formation
between tissue, e.g., organ, surfaces in body cavities and
as an intracavity carrier device for delivering
10 pharmaceutical agents.

BACKGROUND OF THE INVENTION

Adhesion formation, in particular following peritoneal
surgery, is a major source of postoperative morbidity and
mortality. Appendectomy and gynecologic surgery are the
15 most frequent surgical procedures implicated in clinically
significant adhesion formation. The most serious
complication of intraperitoneal adhesions is intestinal
obstruction; in addition, adhesions are associated with
chronic or recurrent pelvic pain and infertility in
20 females.

The pathogenesis of adhesion formation is complex and
not entirely understood. The first step is believed to
involve excess fibrin deposition to form a scaffold.
Organization of the fibrin scaffold by cellular elements,
25 including fibroblasts and mesothelial cells, then follows.

Various approaches for the prevention of adhesion
formation have been actively explored [diZerega, G.S. &
Rodgers, K.E., "Prevention of Postoperative Adhesions," in
"The Peritoneum," diZerega, G.S. & Rodgers, K.E., eds.,
30 Springer-Verlag, New York, pp. 307-369 (1992)]. In
general, the treatments fall into three categories:
prevention of fibrin deposition in the peritoneal exudate,
reduction of local tissue inflammation; and removal of
fibrin deposits.

Therapeutic attempts to prevent fibrin deposition include peritoneal lavages to dilute or wash away fibrinous exudate, surgical techniques to minimize tissue ischemia and introduction of barriers to limit apposition of healing serosal surfaces. Although the use of agents affecting coagulation of the fibrinous fluid has also been proposed, results obtained to date suggest that the use of procoagulants in areas of substantial bleeding may actually promote adhesion formation [Elkins, T.E., "Can a Pro-Coagulant Substance Prevent Adhesions?" in "Treatment of Post-Surgical Adhesions," diZerega, G.S. et al., eds., Wiley-Liss, New York, pp. 103-112 (1990)].

Physical barriers have been used in attempts to prevent adhesion formation by limiting tissue apposition during the critical period of peritoneal healing, thereby minimizing the development of fibrin matrix between tissue surfaces. Barrier agents which have been employed include both mechanical barriers and viscous solutions. Mixed results have been obtained using a barrier comprising a thin sheet of expanded poly-tetrafluoroethylene; in any event, such a membrane is less than ideal, as it must be sutured into place and is nonabsorbable. While an absorbable barrier (for example, a barrier made of oxidized regenerated cellulose) would be preferable, not all studies have demonstrated the efficacy of such barriers in preventing adhesions. Liquid barriers have also been considered for use in preventing adhesions; for example, chondroitin sulfate and carboxymethyl cellulose have both shown some promise in animal models. In addition, solution of dextran 70 (molecular weight = 70,000) has been the subject of a number of clinical studies. Not all clinical evaluations of 32% dextran 70 have found a therapeutic effect, however, and the clinical use of the solution is also associated with clinically important side effects.

Anti-inflammatory drugs have been evaluated for their

effects on postoperative adhesion formation, as they may limit the release of fibrinous exudate in response to inflammation at the surgical site. Two general classes of these drugs were tested: corticosteroids and nonsteroidal anti-inflammatory drugs. The results of corticosteroid use in animal studies have generally not been encouraging, and clinical use of corticosteroids is limited by their other pharmacologic properties. While experimental evaluations of nonsteroidal anti-inflammatory drugs in postoperative adhesion formation show promise [Rodgers, K.E., "Nonsteroidal anti-inflammatory drugs (NSAIDs) in the treatment of Postsurgical adhesion," in "Treatment of Post-Surgical Adhesions," diZerega, G.S. et al., eds., Wiley-Liss, New York, pp. 119-129 (1990)], clinical evaluation of these drugs for adhesion prevention is needed.

The third approach explored to date involves the removal of fibrin deposits. Although proteolytic enzymes (e.g., pepsin, trypsin and papain) should theoretically augment the local fibrinolytic system and limit adhesion formation, these enzymes are rapidly neutralized by peritoneal exudates rendering them virtually useless for adhesion prophylaxis. While various fibrinolytics (for example, fibrinolysin, streptokinase and urokinase) have been advocated, a potential complication to the clinical use of these enzymes in postoperative therapy is excessive bleeding resulting from their administration. Topical application of a recombinant tissue plasminogen activator (rt-PA) has been shown to reduce adhesion formation in a variety of animal models; further research is necessary to develop suitable delivery systems to provide this drug to the surgical site and identify the postoperative time when adhesion prevention is feasible.

To date, no single therapeutic approach has proven universally effective in preventing formation of

postoperative intraperitoneal adhesions. Therefore, there is a need for compositions and methods which may be used safely and effectively to reduce or prevent postoperative adhesion formation in a variety of different contexts.

5 OBJECTS OF THE INVENTION

 It is an object of the present invention to provide hydroxyethyl starch (HES) for use as an absorbable mechanical barrier in a method for reducing or preventing adhesion formation at intracavitary injury sites following
10 surgical procedures. HES can be effectively used alone or in combination with one or more anti-adhesion formation compounds.

 It is another object of the invention to provide HES for use as intracavitary delivery device for delivering
15 pharmaceutically active agents into body cavities.

 These and other objects of the invention will be apparent in light of the detailed description below.

SUMMARY OF THE INVENTION

 The present invention relates to HES and its utility
20 in medical treatment. In one embodiment of the invention, HES is employed as an absorbable mechanical barrier for reducing or preventing post-surgical adhesion formation between tissue, e.g., organ, surfaces at the injury site in a body cavity during tissue repair. The absorbable
25 mechanical barrier remains at a site of potential adhesion formation for a period of time sufficient to permit substantial tissue repair (e.g., re-epithelialization or mesothelial repair) at the injury site. If desired, the HES barrier may include one or more compounds which reduce
30 adhesion formation for an enhancement of this effect. Representative compounds having anti-adhesion formation effects include quinacrine, dipyridamole and analogs thereof, ketotifen and analogs thereof, manoalide and

analogs thereof, retinoids, lazaroids, and an anti-inflammatory corticosteroid, betamethasone.

In another embodiment of the present invention, HES may be used as an intracavity carrier device for delivering pharmaceutically active agents to tissue, e.g., organ, surfaces in intracavity spaces. The pharmaceutically active agents may be covalently or non-covalently bound to HES or may simply be dispersed within HES.

DETAILED DESCRIPTION OF THE INVENTION

10 All literature references, patents and patent applications cited in this application are incorporated herein in their entirety.

The present invention is based on the discovery that hydroxyethyl starch (HES) is useful in treatment methods as an absorbable mechanical barrier for minimizing or preventing formation of post-surgical adhesions between tissue surfaces in a body cavity and as an intracavity carrier device for delivering pharmaceutically active agents. HES is an amylopectin wherein hydroxyethyl groups have been substituted on a molar basis of between about 0.1 and about 0.8 (that is, one hydroxyethyl group for every 10 glucopyranose units to 8 hydroxyethyl groups for every 10 glucopyranose units), with amylopectin monomers having molecular weights ranging between about 3×10^4 and about 4×10^6 , preferably ranging between about 2×10^5 and about 2.4×10^6 daltons. For a review of HES, see, e.g., Thompson, W.L. (1978) "Hydroxyethyl Starch," in "Blood Substitutes and Plasma Expanders," Alan R. Liss, Inc., New York, NY, pp. 283-292. One form of HES, hetastarch (HES-7-8:10) or Hespan, is used commercially as a plasma volume expander and erythrocyte sedimenting agent and is comprised of more than 90% amylopectin which is etherified to the extent that approximately 7-8 hydroxyl groups present in every 10 D-glucopyranose units of the polymer have been

converted to $\text{CH}_2\text{CH}_2\text{OH}$ groups. See "1993 Physicians' Desk Reference," pp. 967-68. In the Examples that follow, two forms of HES were evaluated: one form has one $\text{CH}_2\text{CH}_2\text{OH}$ group per 10 glucopyranose units (HES-1:10) and HES-7-8:10.

5 Prior to the present invention, utility of HES as an absorbable mechanical barrier for adhesion formation prevention purposes and as an intracavity carrier device for delivery of pharmaceutically active agents was unknown.

In one embodiment of the invention, HES, e.g., HES-10 1:10 and HES-7-8:10, are employed as an absorbable mechanical barrier for use in minimizing or preventing adhesion formation between tissue surfaces (not cell-to-cell adhesion) in a body cavity, the most common cause of which is prior surgery. HES was found to be effective 15 alone in preventing adhesion formation in the peritoneum following surgery. In addition, the present invention finds utility in other contexts, e.g., for cardiovascular, orthopedic, thoracic, ophthalmic, CNS and other uses, where prevention of the formation of adhesions is a significant 20 concern. For the purposes of the following discussion, attention is directed primarily to description of compositions and methods useful in inhibiting peritoneal adhesion formation.

HES shares gross similarities with dextran with 25 regards to structure and clinical applications. Dextran has been shown to be useful in many clinical and animal studies to reduce adhesion formation. Two possible mechanisms have been proposed for Dextran's anti-adhesion formation effects. One mechanism is based on 30 hydroflotation whereby large amounts of ascites formation was observed following Dextran application due to the hyperosmolality of the material tested. See, for instance, diZerega et al (1994) "Use of Instillates to prevent intraperitoneal Adhesions. Crystalloid and Dextran," 35 Infertility and Reprod. Med. Clinics of North America, Vol.

5, pp. 463-78; and Cohen et al. (1983) "Use of Intraperitoneal Solutions for Preventing pelvic adhesions in the Rat," J. Reprod. Med., Vol. 28, pp. 649-653. The other mechanism is based on alterations in coagulation parameters. Ibid. In the animal studies outlined below, however, HES did not cause the formation of a significant ascites as would be observed with dextran.

Dextran containing formulations have been shown to reduce adhesion formation only when they are hyperosmolar. Ibid. The hyperosmolar formulations lead to ascites formation by the process of equilibration by the movement of fluid into the peritoneal cavity. Ibid. The ascites produces a hydroflotation media to separate tissue by flotation during the process of peritoneal repair. The Examples below show that HES effectively reduces adhesion formation in hyposmolar formulations. Thus, the mechanisms of action in adhesion prevention are distinctly different between dextran and HES. In addition, the literature suggests that HES does not affect fibrinolysis and coagulation to the same extent as dextran.

The effect of HES on coagulation parameters may depend upon the degree of derivatization and the molecular weight. Pentastarch (smaller MW and less derivatization) does not seem to alter coagulation parameters. Strauss et al. (1988) "Pentastarch may cause fewer effects on coagulation than hetastarch," Transfusion, Vol. 28, pp. 257-60; London et al. (1989) "A randomized clinical trial of 10% pentastarch (low molecular weight hydroethyl starch) versus 5% albumin for plasma volume expansion after cardiac operations," J. Thorac. Cardiovasc. Surg., Vol. 97: 785-97; Samana, C. et al. (1991) "Absence of side effects of hydroxyethyl starch 200 in a porcine model of experimental arterial thrombosis," Thrombosis Res., Vol. 62, pp. 591-8.

HES is seemingly cleared by macrophages therefore, there was a theoretical concern for decreased macrophage

function. However, further studies have not supported this. No effect was shown on several WBC functions (phagocytosis, chemotaxis, cytokine release and release of inflammatory mediators). Eastlund, D. (1992) "Monocyte chemotaxis and chemotactic cytokine release after exposure to hydroxyethyl starch," Transfusion, Vol. 32, pp. 855-60; Strauss et al. (1986) "Ingestion of hydroxyethyl starch by human leukocytes," Transfusion, Vol. 26, pp. 88-90; Hain, H. et al. (1988) "Prostaglandin E₂, thromboxane B₂, and leukotriene B₄ release from peritoneal macrophages by different osmotic agents in nonuremic guinea pigs," Trans. Am. Soc. Artif. Intern. Organs, Vol. XXXIV, pp. 429-32.

The observed actions of HES is not in and of itself sufficient to enable one to predict whether it would have any utility in reduction of adhesion formation. For instance, HES shortened the lag time for thrombin-induced clotting time and augmented the lateral association of fibrin fibrils. However, HES also accelerates fibrinolysis, prolongs APTT time and decreases the production and procoagulant activity of Factor VIII. Therefore, the effects of HES on hemostatic parameters is mixed and it is difficult to predict one way or the other what effect, if any, HES would have with respect to adhesion formation. Carr, ME. (1986) "Effect of hydroethyl starch on the structure of thrombin- and reptilase-induced fibrin gels," J. Lab. Clin. Med., Vol. 108, pp. 566-61; Kuitunen, A. et al. (1993) "Hydroethyl starch as a prime for cardiopulmonary bypass: Effects of two different solutions on haemostasis," Acta Anaesthesiologica Scandinavica, Vol. 37, pp. 652-8; Collins, R. et al. (1994) "The effect of hydroxyethyl starch and other plasma volume substitutes on endothelial cell activation: an in vitro study," Intensive Care Med., Vol. 20, pp. 37-41; Folk, JL et al. (1988) "Effects of hetastarch and albumin

on coagulation in patients with septic shock," J. Clin. Pharmacol., Vol. 28, pp. 412-5.

HES employed in the invention are amylopectins wherein hydroxyethyl groups have been substituted on a molar ratio ranging between about 0.1 and about 0.8 of a hydroxyethyl group per glucopyranose unit. The amylopectin monomers may have molecular weights ranging between about 3×10^4 and about 4×10^6 daltons, preferably ranging between about 2×10^5 and about 2.4×10^6 daltons. Preferred HES in practicing this invention are HES-1:10, HES-7-8:10 and HES-5:10 (commonly referred to as pentastarch). HES may be purchased from a variety of commercial sources including Sigma Chemical Company (St. Louis, MO, USA).

If desired, aggregated or crosslinked forms of HES may be used in the HES formulations of the present invention. Methods for inducing interactions between HES monomers are known in the art and include heating or irradiation. See, for example, Concettoni et al. (1992) "Thermic and UV instability of hetastarch," Pharmacological Res., Vol. 25, pp. 87-88; and Concettoni et al. (1990) "Energy of Activation of hetastarch in a limited range of thermal exposition," Acta Physiologica Hungaria, Vol. 75 (Supp.), pp 59-60.

HES formulations may be prepared by dissolving a predetermined amount in water at temperatures ranging between about 25°C and about 100°C. It has been observed that HES-7-8:10 readily dissolves in water at room temperature while HES-1:10 requires higher temperatures, e.g., 100°C, to dissolve.

If desired, the HES stock solution is centrifuged to remove particulate matter and sterilized by autoclaving, by sterile filtration, or any suitable method. Upon cooling to room temperature, the sterile stock solution is diluted in appropriate volumes of a sterile physiologically acceptable vehicle to produce an HES formulation.

-10-

In general, the concentration of HES which can be administered would be limited by efficacy at the lower end and solubility or toxicity of the material at the upper end. In practice, the concentration of HES formulations generally range between about 0.1% and about 60% (w/v), preferably ranging between about 5.4% and about 34.3% (w/v), of HES in an aqueous vehicle. At the aforementioned concentration ranges, the HES formulations are hypotonic so as to avoid hydroflotation and its resulting adverse physiological effects. However, any osmolarity can be provided, for instance, the compositions of the invention can be formulated so as to be isotonic or hypertonic to body tissues in a body cavity. Osmolarity can be adjusted by varying the amounts of HES used or using physiologically acceptable osmotically active substances.

HES formulations may be stored at a temperature generally ranging between about -20°C and about 30°C, preferably ranging between about 4°C and about 25°C, prior to use. An enhanced anti-adhesion formation effect was observed following storage of certain HES formulations, e.g., 13.5% HES-1:10, at 4°C prior to administration. Without being bound by any theory of operation of the invention, it is believed that low temperature storage had increased the viscosity of the HES composition.

Nonlimiting examples of physiologically acceptable vehicles include water, saline or aqueous buffer solutions containing alkali or alkaline earth metal carbonates, phosphates, bicarbonates, citrates, borates, acetates, succinates and the like, such as sodium phosphate, citrate, borate, acetate, bicarbonate, carbonate and tromethamine (TRIS). The physiologically acceptable vehicles should not cause or aggravate irritation or inflammation on contact with the targeted site for application. Preferred vehicles for use in this invention include saline, phosphate buffered saline (PBS), citrate buffer, and Ringers lactate

solution.

In practicing the present invention, it is preferred that HES compositions be further supplemented with anti-adhesion formation compounds for enhanced effect.

5 Representative anti-adhesion formation compounds include the ones described, for instance, in U.S. Patent application Ser. No. 08/341,651, filed November 17, 1994 for lazarooids; U.S. patent application Ser. No. 08/253,438, filed June 7, 1994, for quinacrine; U.S. patent application

10 Ser. No. 08/373,399, filed January 16, 1995 for retinoids; U.S. Patent application Ser. No. 08/253,437, filed June 7, 1994 for dipyridamole; U.S. Patent application Ser. No. 08/473,183, filed concurrently with the present application, for METHOD FOR REDUCING OR PREVENTING POST-

15 SURGICAL ADHESION FORMATION USING 5-LIPOXYGENASE INHIBITORS by Kathleen Elizabeth Rodgers and Gere Stodder diZerega (University of Southern California, assignee); U.S. Patent application Ser. No. 08/479,128, filed concurrently with the present application, for METHOD FOR REDUCING OR

20 PREVENTING POST-SURGICAL ADHESION FORMATION USING MANOALIDE AND ANALOGUES THEREOF by Kathleen Elizabeth Rodgers and Gere Stodder diZerega (University of Southern California, assignee); and U.S. Patent application Ser. No. 08/472,299, filed concurrently with the present application, for METHOD

25 FOR REDUCING OR PREVENTING POST-SURGICAL ADHESION FORMATION USING KETOTIFEN AND ANALOGS by Kathleen Elizabeth Rodgers and Gere Stodder diZerega (University of Southern California, assignee). Other representative anti-adhesion formation agents include NSAIDS such as Tolmetin and

30 Ibuprofen; and anti-inflammatory corticosteroids such as Betamethasone and Dexamethasone. Betamethasone is a particularly potent anti-adhesion formation agent and its use in conjunction with the HES composition of the present invention is exemplified in the Examples below.

If desired, the HES formulations of the present invention may also contain preservatives, cosolvents, suspending agents, viscosity enhancing agents, ionic strength and osmolality adjustors and other excipients in addition to buffering agents. Suitable water soluble preservatives which may be employed in the drug delivery vehicle include sodium bisulfite, sodium thiosulfate, ascorbate, benzalkonium chloride, chlorobutanol, thimerosal, phenylmercuric borate, parabens, benzyl alcohol, phenylethanol or antioxidants such as Vitamin E and tocopherol and chelators such as EDTA and EGTA. These agents may be present, generally, in amounts of about 0.001% to about 5% by weight and, preferably, in the amount of about 0.01 to about 2% by weight.

Pursuant to the method of the present invention, HES is maintained in an effective concentration at the site of potential adhesion formation for a period of time sufficient to permit substantial reepithelialization. HES is typically administered over the intraoperative interval, which for purposes of the present invention may include the time at the beginning of surgery through the surgery itself up to some time just prior to completion of surgery. In practicing the invention, the HES composition is preferably administered in a single dose (for example, prior to skin closure after surgery). If desired, the HES composition may be administered repeatedly during surgery. In general, the amount of HES formulation which may administered at the injury site ranges between about 0.2 and about 100 ml/Kg body weight, preferably ranging between about 2 and about 10 ml/Kg body weight.

In another embodiment of the invention, HES formulations may be used as an intracavity carrier device to deliver a pharmaceutically active agent to a targeted body cavity such as the rectum, urethra, nasal cavity, vagina, auditory meatus, oral cavity, buccal pouch,

peritoneum, pleura, articular space, central nervous system (e.g., intradural spaces) tendinous space, paraspinal space. As would be readily apparent to one working in the field, the pharmaceutical agent may be covalently or
5 non-covalently (e.g., ionically) bound to such a barrier, or it may simply be dispersed therein.

When used as a intracavity carrier device, the HES formulations contain an effective amount of a pharmaceutically active agent such as a drug, generally
10 ranging from between about 0.001% to about 10% by weight of the agent, preferably ranging between about 0.01% and about 5%. Co-solvents such as DMSO or ethanol may be used to enhance drug solubility of water insoluble pharmaceutically active agents. Insoluble drugs can often be suspended with
15 the aid of suitable suspending or viscosity-enhancing agents.

Suitable, but non-limiting classes of pharmaceutically active agents which can be administered to a body cavity by the intracavity carrier device of the present invention
20 include antibacterial substances such as β -lactam antibiotics like cefoxitin, penicillin, clindamycin, metronidazole, ampicillin, cephalosporin, n-formamidoyl thienamycin and other thienamycin derivatives, tetracyclines, chloramphenicol, neomycin, gramicidin,
25 bacitracin, sulfonamides; aminoglycoside antibiotics such as gentamycin, kanamycin, amikacin, sisomicin and tobramycin; nalidixic acids and analogs such as norfloxacin and the antimicrobial combination of fluoro-alanine/pentizidone; nitrofurazones, and the like;
30 antihistaminics and decongestants such as pyrilamine, chlorpheniramine, tetrahydrozoline, antazoline, and the like; anti-inflammatories such as cortisone, hydrocortisone, betamethasone, dexamethasone, fluocortisone, prednisolone, triamcinolone corticosteroids,
35 indomethacin, sulindac, ibuprofen, tolmetin and

flubiprofen, its salts and its corresponding sulfide, and the like. Also included are antiviral compounds such as acyclovir; fibrinolytic enzymes such as tissue plasminogen activator, streptokinase, and urokinase; cytokines such as
5 tumor necrosis factor, interleukin-1, and interferon; and growth factors such as epidermal growth factor, and transforming growth factor as classes of compounds to deliver via this vehicle.

For treatment of vaginal and urethral conditions
10 requiring antifungal, amoebocidal, trichomonacidal agents or antiprotozoals, the following agents can be used: polyoxyethylene nonylphenol, alkylaryl sulfonate, oxyquinolin sulfate, miconazole nitrate, sulfanilamide, candicidin, sulfisoxazole, mystatin, chlortrimazole,
15 metronidazole and the like and antiprotozoals such as chloramphenicol, chloroquine, trimethoprim, sulfamethoxazole and the like, antineoplastics such as cisplatin and 5-fluorouracil.

The compositions of the present invention may be
20 applied to the targeted site by any suitable means. In general, intracavitary administration is dependent upon the body space, e.g. pouring into the peritoneal cavity and injection into the intra-articular space.

The invention may be better understood with reference
25 to the accompanying examples, which are intended to be illustrative only and should not be viewed as in any sense limiting the scope of the invention, which is defined hereinafter in the accompanying claims.

Examples

30 Multiple studies were performed to confirm the efficacy of HES compositions alone or in combination with an anti-adhesion compound in the reduction of adhesion formation following peritoneal surgery. Two model systems were employed: the sidewall adhesion model and the uterine
35 horn model. A clear correlation between results obtained

using both of these models and utility in adhesion prevention has been demonstrated with INTERCEED(TC7), for which clear clinical efficacy has been shown and FDA approval for adhesion prevention in gynecological surgery
5 has been obtained.

In the peritoneal sidewall model, rabbits were pre-anesthetized with 1.2 mg/kg acetylpromazine and anesthetized with a mixture of 55 mg/kg ketamine hydrochloride and 5 mg/kg xylazine intramuscularly.
10 Following preparation for sterile surgery, a midline laparotomy was performed. A 3 x 5-cm area of peritoneum and transversus abdominis muscle was removed on the right lateral abdominal wall. The cecum was exteriorized, and digital pressure was exerted to create subserosal
15 hemorrhages over all cecal surfaces. The cecum was then returned to its normal anatomic position. The compound to be tested was placed in an Alzet miniosmotic pump (Alza Corporation, Palo Alto, CA, USA) to allow continuous release of the molecule through the postsurgical interval.
20 The Alzet miniosmotic pump was placed in the subcutaneous space and a delivery tube connected the pump with the site of injury at sidewall. Vehicle was placed in the pump of control rabbits. The abdominal wall and skin were closed in a standardized manner.

25 After 7 days, the rabbits were sacrificed and the percentage of the area of the sidewall injury that is involved in adhesions was determined. In addition, the tenacity of the adhesion formed was scored using a system as follows:

30 0 = No adhesions
 1 = mild, easily dissectable adhesions
 2 = moderate adhesions; non-dissectable, does not tear organ

-16-

3 = dense adhesions; non-dissectable, tears
when removed

A reduction in the area or the tenacity of the adhesions would be considered beneficial.

5 In additional experiments, a rabbit uterine horn model was employed. This model has been previously shown to cause severe adhesions in rabbits after surgery [Nishimura, K. et al., "The Use of Ibuprofen for the Prevention of Postoperative Adhesions in Rabbits," Am. J. Med., Vol. 77, 10 pp. 102-106 (1984)]. The rabbits were anesthetized (130 mg/kg ketamine and 20 mg/kg acetylpromazine im) and prepared for sterile surgery. A midline laparotomy was performed and both uterine horns were surgically traumatized by abrading the serosal surface with gauze 15 until punctate bleeding developed. Ischemia of both uterine horns was induced by removal of the collateral blood supply. In some studies, the materials were delivered to the site of injury via Alzet miniosmotic pumps and tubes as described above. In other studies, a portion 20 of the test compositions were applied at the site of injury at the end of surgery and any remaining material was applied through the incision site prior to closing. Controls include surgical and vehicle controls. The abdominal wall and skin were closed in a standardized 25 manner.

After 7 days, the rabbits were sacrificed and the percentage of the area of the uterine horn injury that is involved in adhesions was determined. An initial score to represent the overall extent of adhesions is given (0 to 30 4+). The percentage of a surface of the horn involved in adhesions to various organs are given in the tables below the overall adhesion score.

In the model systems employed in the examples reported herein, compositions comprising HES were shown to reduce

the incidence of peritoneal adhesions. In these Examples, rabbits received various volumes of test composition. The HES concentration of the test compositions ranged from between about 5.4% and about 40%. Other test compositions
5 included anti-adhesion drug compounds such as quinacrine, lazaroid and betamethasone.

Example 1: Preparation of HES Compositions

HES-1:10 (6.15 grams, Cat. No. H 6382 Sigma Corporation, St. Louis, MO, USA) was resuspended in water
10 (100 ml) using a magnetic stirrer and heated to 85°C to dissolve the HES-1:10. The solutions were then boiled for approximately 1 minute and allowed to cool. The material was centrifuged for 10 minutes at 1000 x g to remove large
15 pieces of undissolved particulate matter, placed in an autoclave and heated to sterilize. After autoclaving, the preparation was diluted with either vehicle or drug (9 parts HES-1:10 with 1 part vehicle depending upon the test group). Thereafter, the materials were placed in a syringe and stored at room temperature or at 4 C. Storage at room
20 temperature did not appear alter the viscosity of the HES-1:10 solution to the same extent. However, storage at 4 C for 3 to 5 weeks resulted in an increase in viscosity to a point of solidification in the higher percentage HES-1:10 solutions.

25 With respect to HES-7-8:10, a predetermined amount of HES-7-8:10 was diluted in distilled water and mixed at a dilution of 9 parts HES to 1 part 10x drug or vehicle. The percentages were made on a wt/vol basis. After mixing, the formulations were sterilized by filtration or autoclaving.

30 The materials and procedures for preparing HES formulations are as follows:

-18-

Diluents: a) Saline - 0.85% NaCl in deionized or distilled water and autoclaved to sterilize (termed saline in table below); b) PBS - 0.01 M sodium phosphate, 0.1 M NaCl, pH 7.4, autoclave to sterilize;
 5 c) Citrate Buffer - 0.02 M citric acid, 0.0032 M sodium citrate, 0.077 M NaCl, pH 3.5, sterile filter (termed citrate in table below).

Drugs: These were dissolved in an appropriate buffer or salt solution at a concentration 10 fold the final
 10 concentration. The 10x drug solutions were diluted 1:10 with the corresponding sterile HES-1:10 or HES-7-8:10 solution to yield a 1x drug concentration and a 9:10 HES-1:10 concentration. For example, a stock 15%
 15 HES-1:10 solution diluted 9:10 with either saline or 10x drug in saline will give a final 1x drug level in 13.5% HES-1:10.

Osmolality measures of several of the test formulations used in the Examples are given below:

	HES	% (w/v)	Buffer	mmol/kg
20	HES-1:10	5.4%	10% Saline	42
		8.1%	10% Saline	36
		10.8%	10% Saline	46
		13.5%	10% Saline	47
		5.4%	10% Citrate	37
		8.1%	10% Citrate	38
		10.8%	10% Citrate	48
		13.5%	10% Citrate	42
	HES-7-8:10	9%	Water	47
		12%	Water	52
		15%	Water	62
		18%	Water	102

Example 2: Evaluation of HES-1:10/Quinacrine compositions

In this Example, 10.8% (w/v) or 13.5% (w/v) HES-1:10 compositions alone or in combination with quinacrine (0.5 mg/ml) were evaluated in the rabbit uterine horn model for
5 adhesion prevention. Quinacrine, an antimalarial drug, was found to have a post-surgical anti-adhesion formation effect as disclosed in co-pending U.S. patent application No. 08/253,438, filed June 7, 1994, which is incorporated herein in its entirety. The composition was administered in
10 a volume of 5 ml at the end of surgery and the animals were sacrificed at day 7. The control was surgery only. The statistical analysis based on the data from the double uterine horn model (nonparametric data) was performed on the overall score. The data is rank ordered, a rank value
15 given and an analysis of variance on the ranks is performed. The results are summarized in Tables 1 and 2. HES-1:10 alone and in combination with quinacrine was found to be efficacious in reducing adhesions in the rabbit double uterine horn model.

-20-

TABLE 1
HES-1:10 + Quinacrine

Treatment		Overall Score
Surgical Control		3+
		2.5+
		2.5+
		3+
		3+
5	13.5% RT HES-1:10	2.5+
		2+
		2+
		2+
		Died D3 P/O
	13.5% RT HES-1:10 + Quinacrine	0.5+
		Infection
		1.5+
		1.5+
		1+
	13.5% 4C HES-1:10	2+
		1+
		1.5+
		1.5+
		1.5+
10	13.5% 4C HES-1:10 + Quinacrine	1.5+
		1+

-21-

Treatment	Overall Score
	1.5+
	1.5+
	2+
10.8% RT HES-1:10	2+
	2+
	1+
	2.5+
	1+
10.8% RT HES-1:10 + quinacrine	2+
	1.5+
	1.5+
	1+
	1.5+
10.8% 4C HES-1:10	1.5+
	2.5+
	1+
	Died D1 P/O
	2+
5 10.8% 4C HES-1:10 + quinacrine	1.5+
	1+
	2+
	1.5+
	1.5+

-22-

Treatment	Overall Score
0.5 mg/ml Quinacrine	1.5+
	1.5+
	1+
	1+
	1.5+

TABLE 2
% Organ Involvement in Uterine
Horn Adhesion

	Treatment	Right Horn				Left Horn			
		Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right
5	Control	50	50	40	0	50	50	50	0
		30	50	30	0	30	50	40	0
		30	30	40	20	30	30	30	20
		30	40	50	30	30	40	50	30
		40	50	40	40	40	50	20	40+
	Mean	36	44	40	18	36	44	40	18
	13.5% RT HES-1:10	30	30	20	20	30	30	30	20
		0	20	20	20	0	20	20	20
		30	10	30	10	30	10	20	10*
		20	10	30	20	20	10	20	20
		DIED D3 P/O							
	Mean	20	17.5	25	17.5	20	17.5	22.5	17.5
10	13.5% RT HES-1:10 + Quinacrine	0	0	10	0	0	0	20	0
		INFECTION							
		10	0	20	20	10	0	20	20
		0	10	30	10	0	10	0	10
		0	0	20	10	0	0	10	10*
	Mean	2.5	2.5	20	10	2.5	2.5	12.5	10
15	13.5% 4C HES-1:10	20	0	30	10	40	0	0	10
		0	20	10	0	0	20	20	0
		0	10	20	10	0	10	10	10

-24-

	Treatment	Right Horn				Left Horn			
		Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right
		0	10	20	20	0	10	30	20
		10	0	10	10	10	0	10	10
	Mean	6	8	18	10	10	8	14	10
	13.5% 4C HES-1:10 + Quinacrine	10	10	10	0	10	10	20	0
		0	20	20	0	0	20	20	0
		0	10	20	30	0	10	20	30*
		0	0	40	10	0	0	30	10*
		20	30	20	20	20	30	20	20*
5	Mean	6	14	22	12	6	14	22	12
	10.8% RT HES-1:10	0	50	30	0	0	50	30	0
		0	30	20	10	0	30	30	10
		10	20	20	0	0	20	0	0
		10	20	30	40	10	20	40	40
		0	10	10	10	0	10	10	10
	Mean	4	26	20	12	2	26	22	12
10	10.8% RT HES-1:10+ Quinacrine	30	10	20	0	30	10	30	0
		20	10	10	0	20	10	0	0
		0	10	30	30	0	10	30	30
		0	10	0	0	0	10	10	0
		0	20	20	10	0	20	20	10*
	Mean	10	12	16	8	10	12	18	8
	10.8% 4C HES-1:10	0	20	20	20	0	20	20	20
		20	10	10	10	20	10	10	10+,*
		0	0	20	10	0	0	20	10

DIED D1 P/O

-25-

Treatment	Right Horn				Left Horn			
	Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right
	0	40	30	20	0	40	20	20
Mean	5	17.5	20	15	5	17.5	17.5	15
10.8% 4C HES-1:10 + Quinacrine	10	0	20	10	10	0	30	10
	10	0	10	0	0	0	20	0
	20	10	20	10	20	10	0	10*
	10	0	30	20	10	0	0	20*
	0	20	20	20	0	20	10	20
5 Mean	10	6	20	12	8	6	12	12
Quinacrine	10	10	30	20	10	10	30	20
	0	0	30	10	0	0	30	10
	0	0	20	10	0	0	20	10
	0	10	30	0	0	0	20	0
	0	0	30	10	0	0	30	10
Mean	2	4	28	10	2	2	26	10

* Material present on horns

+ Horns with incision

10 RT HES-1:10 stored at room temperature, any viscosity due to concentration of HES-1:10 (this terminology was used throughout the patent)

4C HES-1:10 stored in a refrigerator, this increased viscosity (this terminology was used throughout the patent)

15

Statistical analysis was performed on the overall score of the nonparametric data taken from Table 1. The data was rank ordered and assigned a rank value. Analysis of the variance of the ranks was then performed and the resulting student t test results are summarized below. Comparison of the rank order of 13.5% RT HES-1:10 with 13.5% RT HES-1:10 + quinacrine gives a p value of 0.000.

	Treatment	Rank order	p value
	Control	44.4 \pm 2.0	
10	13.5% RT HES-1:10	36.4 \pm 3.3	0.001
	13.5% RT HES-1:10 + quinacrine	12.1 \pm 8.6	0.000
15	13.5% 4C HES-1:10	20.5 \pm 8.9	0.000
	13.5% 4C HES-1:10 + quinacrine	20.5 \pm 8.9	0.000
20	10.8% RT HES-1:10	24.8 \pm 15.2	0.021
	10.8% RT HES-1:10 + quinacrine	20.5 \pm 8.9	0.000
25	10.8% 4C HES-1:10	25.9 \pm 13.6	0.017
	10.8% 4C HES-1:10 + quinacrine	20.5 \pm 8.9	0.000
30	Quinacrine	14.9 \pm 3.1	0.000

Example 3: Evaluation of HES-1:10/Quinacrine compositions

This Example is similar to Example 2, except that 5.4% (w/v) and 8.1% (w/v) HES-1:10 compositions alone or in combination with (0.5 mg/ml) quinacrine were evaluated for adhesion prevention. The composition was administered at

the end of surgery in a volume of 5 ml and the animals were sacrificed at day 7. One control was treated with saline vehicle (termed saline on the table) and the other had surgery only (surgical control). The statistical analysis
5 based on the data from the double uterine horn model (nonparametric data) was performed on the overall score. The data is rank ordered, a rank value given and an analysis of variance on the ranks is performed. The results are summarized in Tables 3 and 4. HES-1:10 alone
10 and in combination with quinacrine was efficacious at the reduction of adhesions in the rabbit double uterine horn model.

-28-

TABLE 3
HES-1:10 + Quinacrine

Treatment		Overall Score
Surgical Control		3+
		2.5+
		2.5+
		2.5+
		2.5+
5	8.1% RT HES-1:10	1.5+
		1+
		0.5+
		1.5+
		1.5+
	8.1% RT HES-1:10 + Quinacrine	2+
		1.5+
		2+
		1+
		1+
	8.1% 4C HES-1:10	2+
		1.5+
		1+
		2.5+
		1.5+
10	8.1% 4C HES-1:10 + Quinacrine	1.5+
		0.5+

Treatment	Overall Score
	1+
	1+
	1+
5.4% RT HES-1:10	2+
	1.5+
	2.5+
	2.5+
	1.5+
5.4% RT HES-1:10 + Quinacrine	1+
	Died
	1.5+
	1.5+
	1.5+
5.4% 4C HES-1:10	2+
	1.5+
	1.5+
	2+
	1.5+
5 5.4% 4C HES-1:10 + Quinacrine	1.5+
	2+
	1.5+
	1+
	1.5+

-30-

Treatment

Overall Score

Saline

1.5+

2+

2+

2.5+

1.5+

TABLE 4
% Organ Involvement in Uterine
Horn Adhesion

	Treatment	Right Horn				Left Horn			
		Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right
5	Control	0	100	30	30	0	100	30	30
		0	60	30	30	0	60	20	30
		0	50	40	30	0	50	30	30
		20	30	40	40	20	30	30	40
		30	20	20	20	30	20	30	20
	Mean	10	52	32	30	10	52	28	30
	8.1% RT HES- 1:10	0	20	20	0	0	20	20	0
		0	10	20	0	0	10	10	0
		0	0	20	0	0	0	10	0*
		10	10	20	10	10	10	20	10+
		0	20	20	0	0	20	20	0
	Mean	2	12	20	2	2	12	16	2
10	8.1% RT HES- 1:10 + Quinacrine	20	30	20	0	20	30	10	0
		0	20	20	0	0	20	10	0
		10	10	30	10	10	10	20	10*
		0	0	20	10	0	0	20	10
		0	20	20	0	0	20	20	0
	Mean	6	16	22	4	6	16	16	4
15	8.1% 4C HES- 1:10	10	20	20	10	10	20	30	10
		10	10	20	10	10	10	0	10
		0	20	20	0	0	20	0	0

-32-

	Treatment	Right Horn				Left Horn			
		Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right
		30	30	20	20	30	30	20	20+
		20	0	10	10	20	0	10	10+
	Mean	14	16	18	10	14	16	12	10
	8.1% 4C HES- 1:10 + Quinacrine	0	10	10	10	0	10	10	10
		0	0	10	0	0	10	0	0
		0	0	10	10	0	0	10	10*
		0	0	10	10	0	0	30	10
		0	0	20	0	0	10	10	0
5	Mean	0	2	12	6	0	6	10	6
	5.4% RT HES- 1:10	20	10	10	10	20	10	10	10
		0	10	10	10	0	10	20	10
		40	10	30	30	40	10	20	30
		30	10	20	20	30	10	20	20
		20	20	0	0	20	20	20	0
	Mean	22	12	14	14	22	12	18	14
10	5.4% RT HES- 1:10 + Quinacrine	0	0	20	20	0	0	10	20
		DIED							
		10	10	10	10	10	10	10	10
		0	10	20	20	0	10	20	20
		10	0	10	20	10	0	20	20
	Mean	5	5	15	17.5	5	5	15	17.5
	5.4% 4C HES- 1:10	10	20	20	10	10	20	10	10
		10	10	20	0	10	10	10	0
		10	0	20	0	10	0	20	0
		20	0	20	30	20	0	20	30

-33-

Treatment	Right Horn				Left Horn			
	Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right
	10	20	20	0	10	20	20	0
Mean	12	10	20	8	12	10	16	8
5.4% 4C HES- 1:10 + Quinacrine	0	20	20	0	0	20	20	0
	10	10	20	0	0	10	20	0
	10	10	20	10	10	10	20	10
	0	0	10	10	0	0	10	10
	20	0	20	20	20	0	20	20
5 Mean	8	8	18	8	6	8	18	8
Saline	0	10	20	10	0	10	10	10
	20	30	20	20	20	30	20	20
	30	30	0	20	30	30	0	20
	10	30	20	40	10	30	20	40
	10	0	20	10	10	0	10	10
Mean	14	20	16	20	14	20	12	20

+ Material present on horns

* Small amount of ascites

Statistical analysis was performed on the overall score of the nonparametric data taken from Table 3. The data was rank ordered and assigned a rank value. Analysis of the variance of the ranks was then performed and the resulting student t test results are summarized below. Comparison of the rank order of 8.1% 4C HES-1:10 with 8.1% 4C HES-1:10 + quinacrine gives a p value of 0.029 and comparison of 5.4% RT HES-1:10 with 5.4% RT HES-1:10 + quinacrine gives a p value of 0.020.

10	Treatment	Rank order	p value
	Control	45.4 \pm 1.8	
	8.1% RT HES-1:10	14.6 \pm 8.6	0.000
15	8.1% RT HES-1:10 + quinacrine	21.5 \pm 13.0	0.004
	8.1% 4C HES-1:10	26.1 \pm 13.1	0.011
20	8.1% 4C HES-1:10 + quinacrine	8.8 \pm 6.7	0.000
	5.4% RT HES-1:10	33.6 \pm 10.4	0.037
25	5.4% RT HES-1:10 + quinacrine	17.9 \pm 6.3	0.000
	5.4% 4C HES-1:10	27.3 \pm 7.1	0.000
30	5.4% 4C HES-1:10 + quinacrine	21.5 \pm 9.2	0.000
	Saline	31.9 \pm 9.0	0.011

Example 4: Evaluation of HES-1:10/Lazaroid Compositions

In this Example, compositions containing 13.5% (w/v), 10.8% (w/v), 8.1% (w/v) or 5.4% (w/v) HES-1:10 alone or in combination with a lazaroid (0.6 mg/ml, U-83836-E, available from the UpJohn Company, Kalamazoo, MI, USA) were evaluated in the rabbit uterine horn model for adhesion prevention. Lazaroids were found to have a post-surgical anti-adhesion formation effect as disclosed in co-pending U.S. patent application No. 08/341,651, filed November 17, 1994, which is incorporated herein in its entirety. The composition was administered in a volume of 5 ml at the end of surgery and the animals were sacrificed at day 7. The control was surgery only. The statistical analysis based on the data from the double uterine horn model (nonparametric data) was performed on the overall score. The data is rank ordered, a rank value given and an analysis of variance on the ranks is performed. The results are summarized in Tables 5 and 6. HES-1:10 alone and in combination with lazaroid was found to be efficacious in reducing adhesions in the rabbit double uterine horn model.

-36-

TABLE 5

HES-1:10 + LAZAROID

Treatment		Overall Adhesion Score
Surgical Control		2+
		2.5+
		2.5+
		2.5+
		2.5+
		3+
		2.5+
		2.5+
		3+
		3+
5	13.5% RT HES-1:10	1.5+
		1.5+
		1.5+
		2+
		1.5+
	13.5% RT HES-1:10 + Lazaroid	2+
		1.5+
		1.5+
		1.5+
		0.5+*
	13.5% 4C HES-1:10	1.5+
		1.5+
		1.5+

-37-

Treatment	Overall Adhesion Score
	1.5+
	1.5+*
13.5% 4C HES-1:10 + Lazaroid	1.5+
	2+
	1.5+
	1.5+
	1.5+
10.8% RT HES-1:10	0.5+
	2.5+
	2.5+
	2+
	1.5+*
5 10.8% RT HES-1:10 + Lazaroid	1.5+
	2+
	1.5+
	1+
	1+*
10.8% 4C HES-1:10	2+
	1.5+
	2+
	2+
	1.5+*

-38-

Treatment		Overall Adhesion Score
10.8% 4C HES-1:10 + Lazaroid		2+
		1+
		1+
		2+
		1+*
8.1% RT HES-1:10		2+
		2+
		3+
		1.5+
		1.5+
5 8.1% RT HES-1:10 + Lazaroid		1+
		1.5+
		1.5+
		1.5+
		1+
8.1% 4C HES-1:10		2+
		2.5+
		2+
		2+
		1.5+
8.1% 4C HES-1:10 + Lazaroid		1+
		1.5+
		1+

Treatment	Overall Adhesion Score
	1+
	1+
5.4% RT HES-1:10	2.5+
	1.5+
	1.5+
	1+
	2+
5.4% RT HES-1:10 + Lazaroid	1.5+
	1.5+
	2+
	1.5+
	1.5+
5.4% 4C HES-1:10	2+
	3.5+
	1.5+
	1.5+
	1.5+
5 5.4% 4C HES-1:10 + Lazaroid	1.5+
	1+
	1+
	1.5+
	1.5+

-40-

Treatment		Overall Adhesion Score
0.6 mg/ml Lazaroid (Fresh)		2+
		1.5+
		1+
		1+
		2.5+
5 0.6 mg/ml Lazaroid (Stored RT w/HES-1:10)		2+
		1.5+
		2+
		1+
		1.5+*

10 * These data are from the last day of surgery on the first half of the study. The formulations tested in the animals represented by these data were stored an additional 5 days prior to testing. With storage, an increase in viscosity was probably and this may account for the increase efficacy noted.

-41-

TABLE 6
% Organ Involvement in Uterine
Horn Adhesion

	Treatment	Right Horn				Left Horn			
		Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right
5	Control	20	10	20	20	20	10	10	20
		40	20	20	20	40	20	20	20
		20	20	20	30	20	20	20	30
		10	40	20	0	10	40	20	0+
		30	30	20	40	30	30	20	40+
		30	30	20	30	30	30	30	30+
		30	10	20	40	30	10	20	40
		30	30	40	20	30	30	40	20
		40	20	20	20	40	20	20	20+
		50	20	40	30	50	30	40	30
	Mean	30	23	24	25	30	23	24	25
	13.5% RT HES-1:10	0	0	30	20	0	0	20	20
		10	20	20	0	10	20	10	0
		20	0	10	20	20	0	10	20
		20	10	20	0	20	10	20	0+
		20	10	20	0	20	10	10	0
	Mean	14	8	20	8	14	8	14	8
10	13.5% RT HES-1:10 + Lazaroid	30	0	10	30	30	0	30	30+
		20	20	20	0	20	20	10	0
		20	0	20	20	20	0	10	20
		10	0	10	10	10	0	20	10
		0	0	20	0	0	0	10	0
	Mean	16	4	16	12	16	4	16	12

- 42 -

	Treatment	Right Horn				Left Horn			
		Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right
5	13.5% 4C HES-1:10	30	0	20	10	30	0	20	10
		0	20	10	10	0	20	10	10
		10	10	10	20	10	10	10	20
		20	20	10	0	20	20	10	0
		20	0	10	10	20	0	10	10
	Mean	16	10	12	10	16	10	12	10
	13.5% 4C HES-1:10 + Lazaroid	20	0	20	0	20	10	10	0**
		20	10	20	10	20	10	10	10
		20	0	10	10	20	0	10	10
		30	0	20	0	30	0	20	0
10		10	20	20	10	10	20	20	10
	Mean	20	6	18	6	20	8	14	6
	10.8% RT HES-1:10	0	0	10	0	0	0	0	0
		10	40	20	0	10	40	20	0
		40	20	20	0	40	20	10	0+
		10	30	20	0	10	30	20	0
		10	10	10	10	10	10	10	10
	Mean	14	20	16	2	14	20	12	2
	10.8% RT HES-1:10 + Lazaroid	30	0	20	0	30	0	20	0**
		10	20	20	0	10	20	20	0**
		30	0	20	0	30	0	0	0
		20	0	10	0	20	0	10	0
		0	0	20	10	0	0	10	10**
	Mean	18	4	18	2	18	4	12	2

-43-

	Treatment	Right Horn				Left Horn			
		Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right
5	10.8% 4C HES-1:10	20	30	30	20	20	30	40	20
		10	0	20	10	10	0	20	10**
		0	40	10	10	0	40	10	10
		10	20	20	0	10	20	10	0+
		10	0	20	10	10	0	20	10
	Mean	10	18	20	10	10	18	20	10
	10.8% 4C HES-1:10 + Lazaroid	20	10	20	20	20	10	20	20
		0	0	20	10	0	0	20	10**
		0	0	20	10	0	0	20	10+
		10	10	20	20	10	10	20	20
		0	10	10	0	0	10	10	0
	Mean	6	6	18	12	6	6	18	12
10	8.1% RT HES-1:10	30	10	30	0	30	10	30	0
		40	0	10	20	40	0	10	20**
		30	0	30	50	30	0	20	50
		20	20	10	10	20	20	0	10**
		0	20	10	20	0	20	10	20
	Mean	24	10	18	20	24	10	14	20
	8.1% RT HES-1:10 + Lazaroid	10	0	0	20	0	0	0	0
		20	0	20	10	20	0	20	10**
		10	0	20	10	10	0	20	10**
		20	40	0	0	20	40	0	0
		20	0	0	0	20	0	10	0
	Mean	16	8	8	8	14	8	10	8

- 44 -

	Treatment	Right Horn				Left Horn			
		Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right
	8.1% 4C HES-1:10	20	0	20	20	20	0	20	20
		40	10	20	20	40	10	20	20
		30	0	30	20	20	0	10	20**
		30	10	20	20	30	10	10	20+
		0	10	10	20	0	10	10	20
	Mean	24	6	22	20	24	6	14	20
5	8.1% 4C HES-1:10 + Lazaroid	0	0	10	10	0	0	20	10+
		30	0	10	10	30	0	10	10**
		0	10	10	0	0	10	10	0
		0	0	10	10	0	0	20	10**
		30	0	10	0	30	0	10	0**
	Mean	12	2	10	6	12	2	14	6
10	5.4% RT HES-1:10	20	0	20	40	20	0	20	40**
		20	10	10	10	20	10	10	10
		20	0	20	10	20	0	20	10+
		0	0	20	10	0	0	20	10
		40	0	10	10	40	0	10	10
	Mean	20	2	16	16	20	2	16	16
	5.4% RT HES-1:10 + Lazaroid	20	0	20	10	20	0	10	10
		20	0	10	10	20	0	20	10
		30	0	30	20	30	0	30	20**
		0	10	20	10	0	10	20	10
		20	0	30	10	20	0	30	10**
	Mean	18	2	22	12	18	2	22	12

-45-

	Treatment	Right Horn				Left Horn			
		Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right
5	5.4% 4C HES-1:10	30	10	10	10	30	10	20	10**
		60	40	30	30	60	40	20	30
		0	30	30	0	0	30	20	0
		0	20	20	10	0	20	20	10
		20	0	20	0	20	0	30	0+
	Mean	22	20	22	10	22	20	22	10
	5.4% 4C HES-1:10 + Lazaroid	0	20	20	20	0	20	0	20
		0	20	10	0	0	20	0	0
		10	0	10	0	10	0	20	0
		20	0	10	10	20	0	10	10**
		10	0	20	20	10	0	20	20**
	Mean	8	8	14	10	8	8	10	10
10	Lazaroid (Fresh)	20	0	20	20	20	0	20	20
		30	0	20	10	30	0	20	10
		10	0	10	0	10	0	10	0
		0	0	10	10	0	0	10	10
		50	20	20	10	50	20	20	10+
	Mean	22	4	16	10	22	4	16	10
	Lazaroid (Stored)	20	0	20	10	20	0	20	10
		10	0	20	10	10	0	20	10
		10	20	20	0	10	20	30	0
		20	0	10	0	20	0	10	0
		20	0	10	10	20	0	10	10
	Mean	16	4	16	6	16	4	18	6

+ Organ with incision

15 ** Material present

RT = HES-1:10 stored at room temperature, any viscosity due

-46-

to concentration of HES-1:10.
 4C = HES-1:10 stored in a refrigerator, this increases viscosity.

Statistical analysis was performed on the overall
 5 score of the nonparametric data taken from Table 5. The
 data was rank ordered and assigned a rank value. Analysis
 of the variance of the ranks was then performed and the
 resulting student t test results are summarized below.
 Comparison of the rank order of 8.1% RT HES-1:10 with 8.1%
 10 RT HES-1:10 + Lazaroid gave a p value of 0.019, 8.1% 4C
 HES-1:10 with 8.1% 4C HES-1:10 + Lazaroid gave a p value of
 0.000, 5.4% RT HES-1:10 with 5.4% RT HES-1:10 + Lazaroid
 gave a p value of 0.042 and 8.1% 4C HES-1:10 + Lazaroid
 with lazardoid gave a p value of 0.030.

15	Treatment	Rank order	p value
	Control	90.6 \pm 6.6	--
	13.5% RT HES-1:10	47.5 \pm 13.0	0.000
20	13.5% RT HES-1:10 + lazardoid	39.6 \pm 22.8	0.000
	13.5% 4C HES-1:10	41.0 \pm 0.00	0.000
25	13.5% 4C HES-1:10 + lazardoid	57.3 \pm 20.6	0.000
	10.8% RT HES-1:10	59.2 \pm 33.9	0.012
30	10.8% RT HES-1:10 + lazardoid	35.5 \pm 23.3	0.000
	10.8% 4C HES-1:10	60.5 \pm 15.9	0.000
35	10.8% 4C HES-1:10 + lazardoid	36.0 \pm 30.6	0.000

-47-

	Treatment	Rank order	p value
	Stored lazaroid	48.0 + 23.5	0.000
	8.1% RT HES- 1:10	63.3 ± 21.7	0.002
5	8.1% RT HES- 1:10 + lazardoid	29.0 ± 14.7	0.000
	8.1% 4C HES- 1:10	70.3 ± 16.0	0.004
10	8.1% 4C HES- 1:10 + lazardoid	17.0 ± 12.0	0.000
	5.4% RT HES- 1:10	51.3 ± 27.7	0.000
15	5.4% RT HES- 1:10 + lazardoid	47.5 ± 13.0	0.000
	5.4% 4C HES- 1:10	59.3 ± 23.9	0.002
20	5.4% 4C HES- 1:10 + lazardoid	29.0 ± 14.7	0.000
	Fresh lazaroid	45.3 ± 32.1	0.000

25 Example 5: Further Evaluation of HES-1:10 Compositions

30 In this Example, various volumes of a HES-1:10 composition were evaluated in the rabbit double uterine horn model for adhesion prevention. The composition was administered in a volumes of 5, 10, 15, and 20 ml at the end of surgery and the animals were sacrificed at day 7. Two sets of experiments were performed using either saline or phosphate buffered saline vehicles. The statistical analysis based on the data from the double uterine horn model (nonparametric data) was performed on the overall score. The data is rank ordered, a rank value given and an

analysis of variance on the ranks is performed. The results are summarized in Tables 7 and 7a (phosphate buffered saline vehicle) and Tables 8 and 8a (saline vehicle). HES-1:10 alone was found to be efficacious in
5 reducing adhesions in the rabbit double uterine horn model.

-49-

TABLE 7

HES-1:10 (in 1/10 PBS) Volume Response

Treatment	Overall Adhesion Score
Surgical Control	2+
	3.5+
	1.5+
	3+
	3+
	3.5+
	1.5+
	3.5+
5 5 ml RT HES-1:10	1+
	1.5+
	1.5+
	2.5+
	1+
	1.5+
	2.5+
10 ml RT HES-1:10	2+
	2+
	2+
	1+
	1+
	1+
	1+
15 ml RT HES-1:10	1+
	2+

-50-

Treatment	Overall Adhesion Score
	1.5+
	2.5+
	2+
	1+
	1+
20 ml RT HES-1:10	1.5+
	1+
	1.5+
	2+
	1.5+
	1.5+
	2+
5 ml 4C HES-1:10	2+
	1+
	2.5+
	2+
	1.5+
	1+
	1.5+
10 ml 4C HES-1:10	1.5+
	1.5+
	1.5+
	1.5+
	1.5+
	1.5+
	3+

Treatment	Overall Adhesion Score
-----------	---------------------------

15 ml 4C HES-1:10	1.5+
	1.5+
	1+
	2+
	1.5+
	1+
	2+

20 ml 4C HES-1:10	2+
	0.5+
	2+
	1.5+
	2+
	1.5+
	1.5+

TABLE 7a
% Organ Involvement in Uterine
Horn Adhesion

	Treatment	Right Horn				Left Horn			
		Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right
5	Control	20	0	30	20	20	0	20	20
		40	50	30	30	40	50	40	30*
		30	0	10	10	30	0	10	10
		40	10	30	30	40	10	40	30
		30	20	30	40	30	20	30	40*
		50	30	30	20	50	30	30	20
		0	10	10	10	0	10	10	10
		30	50	30	40	30	50	30	40
	Mean	30	21.3	25	25	30	21.3	26.3	25
	5 ml RT HES-1:10	20	0	10	0	20	0	10	0
		30	0	10	20	30	0	10	20
		30	0	20	0	30	0	20	0
		20	10	20	20	20	10	20	20
		10	0	10	0	10	0	20	0
		10	0	10	10	10	0	10	10
		30	10	10	40	30	10	20	40
	Mean	21.4	2.9	12.9	12.9	21.4	2.9	15.7	12.9
10	10 ml RT HES-1:10	20	20	10	0	20	20	40	0
		20	20	10	10	20	20	20	10
		0	30	30	30	0	30	30	30
		0	20	10	0	0	20	10	0
		0	0	10	10	0	0	20	10
		20	0	20	0	20	0	20	0
		0	0	10	10	0	0	10	10+
	Mean	8.6	12.9	14.3	7.1	8.6	12.9	21.4	7.1

	Treatment	Right Horn				Left Horn			
		Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right
	15 ml RT HES-1:10	0	10	10	0	0	10	10	0
		0	70	10	0	0	70	20	0
		0	10	10	10	0	10	10	10
		20	20	20	10	20	20	20	10
		30	10	10	10	30	10	10	10*
		0	10	10	0	0	10	10	0
		0	10	20	0	0	10	20	0
	Mean	7.1	20	12.9	4.3	7.1	20	14.3	4.3
5	20 ml RT HES-1:10	0	20	20	10	0	20	20	10
		10	0	20	0	10	0	20	0
		0	10	30	10	0	10	30	10
		30	20	20	0	30	20	20	0
		10	0	20	10	10	0	20	10
		10	10	10	10	10	10	0	10
		20	10	20	20	20	10	20	20+
	Mean	11.4	10	20	8.6	11.4	10	18.6	8.6
	5 ml 4C HES-1:10	20	0	20	20	20	0	20	20
		10	20	0	0	10	20	10	0
		20	30	20	10	20	30	20	10+
		30	20	20	0	30	20	20	0+
		20	10	20	10	20	10	20	10
		10	0	10	0	10	0	10	0
		30	0	20	0	30	0	20	0
	Mean	20	11.4	15.7	5.7	20	11.4	17.1	5.7
10	10 ml 4C HES-1:10	10	0	20	10	10	0	20	10
		20	0	20	20	20	0	20	20
		10	0	20	20	10	0	20	20

-54-

Treatment	Right Horn				Left Horn			
	Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right
	10	10	10	0	10	10	10	0
	10	10	10	10	10	10	10	10
	0	10	10	10	0	10	10	10
	40	20	20	20	40	20	20	20
Mean	14.3	7.1	15.7	12.9	14.3	7.1	15.7	12.9
15 ml 4C HES-1:10	0	20	10	10	0	20	10	10
	0	10	10	20	0	10	10	20
	10	0	10	0	10	0	10	0
	30	0	20	10	30	0	20	10
	20	0	10	10	20	0	10	10+
	10	0	10	0	10	0	10	0
	50	10	10	10	50	10	10	10
Mean	17.1	5.7	11.4	8.6	17.1	5.7	11.4	8.6
5 20 ml 4C HES-1:10	20	10	20	10	20	10	20	10
	0	0	20	0	0	0	20	0
	10	10	20	20	10	10	20	20
	30	0	0	20	30	0	20	20
	30	0	20	20	30	0	20	20+
	20	10	20	0	20	10	10	0
	20	20	20	10	20	20	20	10
Mean	18.6	7.1	17.1	11.4	18.6	7.1	18.6	11.4

* Organ with incision

+ Material present

10 RT = HES-1:10 stored at room temperature, any viscosity due to concentration of HES-1:10

4C = HES-1:10 stored in a refrigerator, this increase viscosity

TABLE 8
HES (10%) in Saline Volume Response

Treatment		Overall Score
Surgical Control		2.5+
		3+
		2.5+
		2.5+
		2.5+
		3+
		2.5+
		3+
5	5 ml RT HES-1:10	1.5+
		1.5+
		2+
		1.5+
		1.5+
		1.5+
		2+
	10 ml RT HES-1:10	1.5+
		1.5+
		1.5+
		2+
		1.5+
		2+
		2.5+
	15 ml RT HES-1:10	1+
		1.5+

-56-

Treatment	Overall Score
	1.5+
	2+
	2+
	2+
	1.5+
20 ml RT HES-1:10	1.5+
	1.5+
	1.5+
	1.5+
	0.5+
	1.5+
	1.5+
5 ml 4C HES-1:10	1+
	1.5+
	2+
	1.5+
	2+
	1.5+
	2+
10 ml 4C HES-1:10	1+
	2+
	2+
	2+
	2+
	2+
	1.5+

-57-

Treatment	Overall Score
15 ml 4C HES-1:10	2+
	2.5+
	2+
	Died
	1.5+
	1+
	2+
20 ml 4C HES-1:10	2.5+
	2+
	1.5+
	1.5+
	1.5+
	1.5+
	2.5+

TABLE 8a
% Organ Involvement in Uterine
Horn Adhesion

	Treatment	Right Horn				Left Horn			
		Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right
5	Control	20	30	20	10	20	30	20	10
		30	30	30	30	30	30	30	30
		30	30	30	30	30	30	20	30+
		30	30	30	20	30	30	20	20
		0	30	30	10	0	30	40	30
		40	30	40	30	40	30	40	30
		20	40	20	20	20	40	30	20+
		30	30	40	30	30	30	40	30
	Mean	25	31.3	30	22.5	25	31.3	30	22.5
	5 ml RT HES-1:10	10	0	10	20	10	0	20	20
		20	0	10	0	20	0	10	0+
		20	10	10	10	20	10	10	10+
		10	0	20	20	10	0	10	20
		20	0	20	20	20	0	20	20
		0	20	30	10	0	20	30	10+
		0	30	10	20	0	30	20	20
	Mean	11.4	8.6	15.7	14.3	11.4	8.6	17.1	14.3
10	10 ml RT HES-1:10	10	10	20	10	10	10	10	10
		20	20	20	0	20	20	10	0
		0	20	20	10	0	20	10	10*
		30	0	20	20	30	0	20	20
		10	0	20	30	10	0	20	30
		30	10	20	20	30	10	10	20
		50	20	20	10	50	20	20	10
	Mean	21.4	11.4	20	14.3	21.4	11.4	14.3	14.3

-59-

	Treatment	Right Horn				Left Horn			
		Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right
5	15 ml RT HES-1:10	10	0	20	0	10	0	20	0
		20	0	10	10	20	0	10	10
		10	10	10	0	10	10	0	0
		20	10	20	10	20	10	20	10*
		30	10	20	20	30	10	20	20+
		30	10	20	10	20	10	20	10*
		20	10	10	10	0	10	10	10
	Mean	15.7	7.1	15.7	8.6	15.7	7.1	14.3	8.6
	20 ml RT HES-1:10	20	0	10	20	20	0	10	20
		10	10	20	0	10	10	20	0
		20	0	20	0	20	0	30	0
		0	10	30	10	0	10	20	10
		0	0	10	0	0	0	20	0
		10	0	10	20	10	0	10	20*
		20	0	10	10	20	0	10	10
	Mean	11.4	2.9	15.7	8.6	11.4	2.9	17.1	8.6
	5 ml 4C HES- 1:10	10	0	0	10	10	0	20	10
		10	10	30	0	10	10	20	0*
		10	0	30	30	10	0	30	30*
		10	0	20	10	10	0	20	10
		30	0	40	20	30	0	30	20*
		20	0	20	10	20	0	20	10*
		20	20	20	30	20	20	20	30
	Mean	15.7	4.3	22.9	15.7	15.7	4.3	22.9	15.7
10	10 ml 4C HES-1:10	10	0	20	0	10	0	20	0
		10	10	20	20	10	10	20	20*

-60-

Treatment	Right Horn				Left Horn					
	Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right		
	20	20	20	20	20	20	20	20*		
	20	10	20	0	20	10	20	0		
	0	20	20	20	0	20	30	20*		
	10	10	10	20	10	10	20	20		
	0	10	20	10	0	10	20	10*		
	Mean	10	11.4	18.6	12.9	10	11.4	21.4	12.9	
	15 ml 4C HES-1:10	20	0	20	30	20	0	20	30*	
		40	10	20	30	40	10	10	30*	
		10	10	20	30	10	10	20	30	
		DIED								
	0	10	10	10	0	10	10	10*		
	0	0	20	10	0	0	20	10		
	20	20	20	10	20	20	20	10*		
	Mean	15	8.3	18.3	20	15	8.3	16.7	20	
	5	20 ml 4C HES-1:10	20	0	20	30	20	0	20	30*
		20	10	20	10	20	10	20	10*	
		0	20	10	10	0	20	10	10+, *	
0		20	10	10	0	20	10	10*		
0		10	10	10	0	10	10	10		
0		20	20	20	0	20	20	20*		
30		0	20	20	30	0	10	20+, *		
Mean		10	11.4	15.7	15.7	10	11.4	14.3	15.7	

+ Organ with Incision

* Material Present

- 10 RT = HES stored at room temperature, any viscosity due to concentration of HES
 4C = HES stored in a refrigerator, this increase viscosity

Statistical analysis was performed on the overall score of the nonparametric data taken from Tables 7 and 8. The data was rank ordered and assigned a rank value. Analysis of the variance of the ranks was then performed and the resulting student t test results are summarized below.

TABLE 7 ANALYSIS

	Treatment	Rank order	p value
	Control	51.4 \pm 14.6	--
10	5 ml RT HES-1:10	30.4 \pm 18.3	0.028
	10 ml RT HES-1:10	25.0 \pm 19.1	0.001
15	15 ml RT HES-1:10	29.1 \pm 19.5	0.025
	20 ml RT HES-1:10	30.4 \pm 12.3	0.011
	5 ml 4C HES-1:10	31.8 \pm 17.7	0.035
20	10 ml 4C HES-1:10	32.1 \pm 11.4	0.014
	15 ml 4C HES-1:10	27.6 \pm 15.6	0.009
25	20 ml 4C HES-1:10	32.1 \pm 15.6	0.028

TABLE 8 ANALYSIS

	Treatment	Rank order	p value
	Control	58.3 \pm 2.9	--
30	5 ml RT HES-1:10	25.6 \pm 10.39	0.000
	10 ml RT HES-1:10	30.9 \pm 14.36	0.000
	15 ml RT HES-1:10	26.6 \pm 14.23	0.000

	Treatment	Rank order	p value
	20 ml RT HES- 1:10	16.4 \pm 6.30	0.000
	5 ml 4C HES- 1:10	26.6 \pm 14.23	0.000
5	10 ml 4C HES- 1:10	33.2 \pm 14.50	0.000
	15 ml 4C HES- 1:10	34.1 \pm 17.47	0.002
10	20 ml 4C HES- 1:10	32.9 \pm 16.57	0.000

Example 6: Side Wall Model Evaluation of Betamethasone

The efficacy of betamethasone in preventing adhesion formation was evaluated in the sidewall model. The drug was delivered for 7 days at a rate of 10 μ l/hr and the animals were sacrificed after 7 days. The vehicle was saline. Relative to the control, betamethasone was efficacious in the sidewall model at the doses tested. Four of the treated rabbits had accumulation of fluid subcutaneously. The results are summarized in Table 9. A student t test analysis of the data was performed and the results are reported in Table 9 as well.

TABLE 9
Betamethasone Sidewall Model

	Treatment	% Adhesions	Adhesion Score
5	Vehicle Control	70%	2+
		0%	0
		90%	3+
		100%	2+
		100%	2+
		90%	2+
	Mean:	75.0% ± 35.0	
	5.0 mg/ml Betamethasone in Vehicle	0%	0+*
		0%	0+
		0%	0+**
		0%	0+
		0%	0+
		Died d3 P/O	
	Mean ^a :	0.0% ± 0.0	
10	0.5 mg/ml Betamethasone in Vehicle	0%	0+
		0%	0+
		0%	0+***
		10%	1+
		100%	1+*
		0%	0+*
	Mean ^b :	18.3% ± 36.7	

* Sidewall was inflamed
** Bleeding intraperitoneally
*** White precipitate
a p = 0.000
5 b p = 0.021

Example 7: Double Uterine Horn Evaluation of Betamethasone

In this Example, compositions containing 0.5 mg/ml and 5.0 mg/ml betamethasone sodium phosphate (Sigma Chemical Co., St. Louis, MO, USA) in saline were evaluated in the rabbit uterine horn model for adhesion prevention. The composition was administered via Alzet miniosmotic pump for 7 days at a rate of 10 ul/hour. The animals were sacrificed at day 7. The vehicle control is saline. The statistical analysis based on the data from the double uterine horn model (nonparametric data) was performed on the overall score. The data is rank ordered, a rank value given and an analysis of variance on the ranks is performed. The results are summarized in Tables 10 and 11. Betamethasone was found to be highly efficacious in the reduction of adhesion formation in the double uterine horn model.

TABLE 10
Betamethasone DUH Model

Treatment		Overall Adhesion Score
Vehicle Control		3.5+
		2.5+
		3+
		2.5+
		3.5+
		3+
5 5.0 mg/ml Betamethasone		0.5+
		1.0+
		1.0+
		1.5+
		1.5+
		Infection
0.5 mg/ml Betamethasone		0.5+
		1+
		1.5+
		1.5+
		0.5+
		1+

TABLE 11
% Organ Involvement in Uterine
Horn Adhesion

	Treatment	Right Horn				Left Horn			
		Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right
5	Control	100	0	50	100	100	0	50	100
		30	30	60	30	30	30	30	30
		40	30	60	50	40	30	50	50**
		30	30	30	40	30	30	30	40
		30	100	40	0	30	100	50	0
		40	60	30	0	40	60	30	0
	Mean	45	41.7	45	36.7	45	41.7	40	36.7
	5.0 mg/ml Betamethasone	0	0	0	10	0	0	0	10
		0	0	30	0	0	0	20	0
		0	0	0	10	0	0	10	10
		0	20	0	20	0	0	0	20
		10	10	20	10	10	10	0	10
	INFECTION								
	Mean	2	6	10	10	2	2	6	10
10	0.5 mg/ml Betamethasone	0	0	0	10	0	0	0	10
		0	0	10	20	0	0	0	20*
		0	10	10	10	10	10	0	10
		20	10	10	10	20	10	10	10*
		0	0	10	0	0	0	0	0
		0	10	20	0	0	10	0	0
	Mean	3.3	5	10	8.3	5	5	1.7	8.3

* Bladder, horn or bowel adhered to the sidewall (at either tube or tube suture)

15 ** Horn and bowel or bladder to sidewall

Statistical analysis was performed on the overall score of the nonparametric data taken from Table 10. The data was rank ordered and assigned a rank value. Analysis of the variance of the ranks was then performed and the resulting student t test results are summarized below.

	Treatment	Rank order	p value
	Control	14.5 \pm 1.63	--
	5 mg/ml Betamethasone	6.4 \pm 2.84	0.000
10	0.5 mg/ml Betamethasone	5.8 \pm 3.06	0.000

Example 8: Kinetic Evaluation of Betamethasone

The efficacy of betamethasone in the double uterine horn model was further evaluated in a kinetics study. In this study, the pump was disconnected at various times after surgery to determine the time period of exposure to the drug effective to reduce adhesion formation. The results are summarized in Tables 12 and 13.

-68-

TABLE 12

Treatment		Overall Adhesion Score
Vehicle Control		3+
		2.5+
		3+
		2.5+
		3.5+
5	5 mg/ml Betamethasone 24 hour D/C	2+
		0.5+
		1+
		1+
		1+
	5 mg/ml Betamethasone 48 hour D/C	Died
		1.5+
		1+
		1+
		1.5+
10	5 mg/ml Betamethasone 72 hour D/C	1.5+
		1.5+
		1.5+
		1.5+
		1+

-69-

Treatment	Overall Adhesion Score
	0.5+
	1+
	1+
	2.5+
0.5 mg/ml Betamethasone 24 hour D/C	Infection
	0.5+
	1.5+
	0.5+
	Died
	1+
5 0.5 mg/ml Betamethasone 48 hr D/C	1.5+
	2+
	1+
	0.5+
	1.5+
	1+
0.5 mg/ml Betamethasone 72 hour D/C	0.5+
	1.5+
	1.5+
	1.5+
	Died
	1+

TABLE 13
% Organ Involvement in Uterine
Horn Adhesion

	Treatment	Right Horn				Left Horn			
		Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right
5	Control	20	60	40	20	20	60	30	20*
		30	40	20	0	30	40	40	0*
		20	40	40	40	20	40	20	40**
		50	30	30	50	50	30	30	50
		20	100	50	20	20	100	30	40
		0	40	10	20	0	40	0	20
	Mean	23.3	51.7	31.7	28.3	23.3	51.7	25.7	28.3
	5 mg/ml Betamethasone 24 D/C	0	0	10	10	0	0	10	10
		0	10	10	0	0	10	10	0*
		0	0	10	10	0	0	0	10
		0	0	10	10	0	0	10	10*
		Died P/O							
10		0	30	0	10	0	30	0 ^b	
10	Mean	2	2	14	6	2	2	10	6
	5 mg/ml Betamethasone 48 hr D/C	0	0	10	20	0	10	10	20
0		0	10	0	0	0	10	0*	
0		10	20	10	0	10	20	10	
0		0	30	20	0	0	10	20*	
10		0	0	0	0	20	30	0*	
0		0	10	20	0	0	10	20	
Mean	1.7	1.7	13.3	11.7	0	6.7	15	11.7	
15	5 mg/ml Betamethasone 72 hr D/C	0	30	20	10	0	30	20	10
		0	0	20	10	0	0	0	10 ^b

-71-

Treatment	Right Horn				Left Horn			
	Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right
	0	0	10	0	0	0	0	0
	0	0	10	20	0	0	10	20
	0	0	10	10	0	0	10	10*
	40	10	10	10	40	10	10	10*
Mean	6.7	6.7	13.3	10	6.7	6.7	8.3	10
0.5 mg/ml Betamethasone 24 hr D/C								
	0	0	10	0	0	0	10	0
	10	0	20	10	10	0	0	10
	0	0	10	0	0	10	0	0
Bleeding and Infection								
	0	0	0	10	0	0	10	0
5 Mean	2.5	0	10	5	2.5	2.5	5	5
0.5 mg/ml Betamethasone 48 hr D/C								
	0	10	20	10	0	0	30	10*
	30	0	10	20	30	0	10	20
	0	0	10	10	0	0	10	10
	0	0	20	0	0	0	20	0 ^b
	0	30	20	0	0	30	20	0
	0	10	10	0	0	10	0	0
Mean	5	8.3	15	6.7	5	6.7	15	6.7
DIED P/O								
10	0	0	0	0	0	0	20	0
	0	10	10	10	0	10	0	10
	0	0	10	10	0	0	30	10*
	0	20	30	0	0	20	10	0
DIED P/O								
	0	20	10	30	0	20	10	30*
Mean	0	10	12	10	0	10	14	10

-72-

- * Bladder, horn or bowel adhered to the sidewall (at either tube or tube suture)
- ** Horn and bowel or bladder to sidewall
- ^a Intraperitoneal bleeding
- 5 ^b Ascites noted

Statistical analysis was performed on the overall score of the nonparametric data taken from Table 12. The data was rank ordered and assigned a rank value. Analysis of the variance of the ranks was then performed and the

10 resulting student t test results are summarized below.

	Treatment	Rank order	p value
	Control	35.1 \pm 2.15	--
15	5 mg/ml betamethasone 24 hour D/C	13.5 \pm 6.83	0.000
	5 mg/ml betamethasone 48 hour D/C	19.0 \pm 6.00	0.000
20	5 mg/ml betamethasone 72 hour D/C	16.9 \pm 9.86	0.001
	0.5 mg/ml betamethasone 24 hour D/C	11.3 \pm 8.84	0.000
25	0.5 mg/ml betamethasone 48 hour D/C	18.5 \pm 9.48	0.002
30	0.5 mg/ml betamethasone 72 hour D/C	18.3 \pm 8.74	0.001

Example 9: Evaluation of HES-1:10/betamethasone Compositions

In this Example, 10.8% (w/v) or 13.5% (w/v) HES-1:10 compositions alone or in combination with (0.5 mg/ml) betamethasone, a synthetic corticosteroid, were evaluated

35 for adhesion prevention. The composition was administered at the end of surgery in a volume of 5 ml and the animals

were sacrificed at day 7. The control was surgery only. The statistical analysis based on the data from the double uterine horn model (nonparametric data) was performed on the overall score. The data is rank ordered, a rank value
5 given and an analysis of variance on the ranks is performed. The results are summarized in Tables 14 and 15. HES-1:10 alone and in combination with betamethasone was efficacious at the reduction of adhesions in the rabbit double uterine horn model.

-74-

TABLE 14
HES-1:10 + Betamethasone

Treatment		Overall Score
Surgical Control		3+
		3+
		2+
		3.5+
		2.5+
5	13.5% RT HES-1:10	1.5+
		1.5+
		1.5+
		1.5+
		1.5+
	13.5% RT HES-1:10 + Betamethasone	1.5+
		1+
		1+
		1+
		1+
	13.5% 4C HES-1:10	Sac D1 P/O
		1.5+
		2+
		1+
		1+
10	13.5% 4C HES-1:10 + Betamethasone	1.5+
		0.5+

-75-

Treatment	Overall Score
	0.5+
	1+
	2+
10.8% RT HES-1:10	1.5+
	2.5+
	0.5+
	1+
	2+
10.8% RT HES-1:10 + Betamethasone	1.5+
	1+
	2+
	1.5+
	1.5+
10.8% 4C HES-1:10	2+
	1+
	1.5+
	2.5+
	1.5+
5 10.8% 4C HES-1:10 + Betamethasone	1.5+
	1.5+
	1.5+
	1.5+
	1.5+

-76-

Treatment

0.5 mg/ml
Betamethasone

Overall Score

1+

1+

2+

1.5+

1.5+

-77-

TABLE 15
% Organ Involvement in Uterine
Horn Adhesion

	Treatment	Right Horn				Left Horn			
		Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right
5	Control	40	20	30	40	40	20	30	40
		40	30	40	50	40	30	40	50
		0	30	30	0	0	30	30	0
		40	50	40	40	40	50	20	40
		0	40	20	0	0	40	20	0
	Mean	24	34	32	26	24	34	28	26
	13.5% RT HES-1:10	0	30	20	0	0	30	20	0
		0	30	20	0	0	30	20	0
		0	30	20	0	0	30	20	0
		10	0	20	10	0	10	20	10
		0	20	20	10	0	20	20	10
	Mean	2	22	20	4	0	24	20	4
10	13.5% RT HES-1:10 + betamethasone	0	20	20	0	0	20	20	0
		10	0	10	0	0	0	10	0
		0	0	20	10	0	0	20	10
		0	10	10	0	0	10	20	0
		0	0	20	10	0	0	20	10
		0	0	20	10	0	0	20	10
	Mean	2	6	16	4	0	6	18	4
15	13.5% 4C HES-1:10	SACRIFICED D1							
		20	0	10	10	20	0	20	10
		10	30	10	0	10	30	10	0
		0	0	0	30	0	0	20	30+
		0	10	30	0	0	10	20	0

-78-

		Right Horn				Left Horn			
		Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right
	Mean	7.5	10	12.5	10	7.5	10	17.5	10
	13.5% 4C HES-1:10 + betamethasone	0	10	20	10	0	0	0	10
		0	0	10	0	0	0	10	0
		0	0	20	0	0	0	10	0
		0	0	10	10	0	0	10	10
		0	0	20	30	0	0	20	30
5	Mean	0	2	16	10	0	0	10	10
	10.8% RT HES-1:10	10	0	30	0	10	0	20	0
		30	30	20	20	30	30	30	20
		0	0	20	0	0	0	20	0+
		0	0	20	10	0	0	20	10
		20	0	20	10	20	0	20	10
	Mean	12	6	22	8	12	6	22	8
10	10.8% RT HES-1:10 + betamethasone	0	0	30	30	0	0	20	30+
		10	0	10	0	0	0	10	0
		0	30	30	20	0	30	30	20
		20	0	10	10	20	0	10	10
		0	10	20	20	0	10	20	20
	Mean	6	8	20	16	4	8	18	16
	10.8% 4C HES-1:10	40	0	20	20	40	0	20	20+
		0	10	10	0	0	10	10	0
		0	20	20	0	0	20	20	0
		40	30	20	20	40	30	20	20
		0	10	20	0	0	10	20	0
15	Mean	16	14	18	8	16	14	18	8

-79-

	Treatment	Right Horn				Left Horn			
		Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right
	10.8% 4C HES-1:10 + betamethasone	0	20	20	0	0	20	20	0
		0	20	20	0	0	20	20	0
		0	20	20	10	0	20	20	10
		10	0	20	10	10	0	20	10
		0	20	20	0	0	20	20	0
	Mean	2	16	20	4	2	16	20	4
5	Betamethasone	0	0	20	10	0	0	10	10
		0	0	20	0	0	10	20	0
		20	10	20	0	20	20	20	0
		10	0	20	30	10	0	20	30
		0	30	20	0	0	30	20	0
	Mean	6	10	20	8	6	12	18	8

+ Material present on horns

Statistical analysis was performed on the overall score of the nonparametric data taken from Table 14. The data was rank ordered and assigned a rank value. Analysis of the variance of the ranks was then performed and the resulting student t test results are summarized below. Comparison of the rank order of 13.5% RT HES-1:10 with 13.5% RT HES-1:10 + betamethasone gave a p value of 0.001.

15	Treatment	Rank order	p value
	Control	45.8 \pm 3.2	--
	13.5% RT HES-1:10	26.0 \pm 0.0	0.000
20	13.5% RT HES-1:10 + betamethasone	12.8 \pm 6.0	0.000

-80-

	13.5% 4C HES- 1:10	21.3 \pm 12.8	0.003
5	13.5% 4C HES- 1:10 + betamethasone	15.9 \pm 14.9	0.002
	10.8% RT HES- 1:10	24.5 \pm 16.7	0.023
10	10.8% RT HES- 1:10 + betamethasone	25.5 \pm 9.7	0.021
	10.8% 4C HES- 1:10	29.3 \pm 12.5	0.021
	10.8% 4C HES- 1:10 + betamethasone	26.0 \pm 0.0	0.000
15	Betamethasone	22.2 \pm 11.6	0.002

Example 10: Evaluation of HES-1:10/betamethasone Composition

In this Example, 8.1% (w/v) and 5.4% (w/v) HES-1:10 compositions alone or in combination with 0.5 mg/ml betamethasone were evaluated in the double uterine horn model for adhesion prevention. The composition was administered at the end of surgery in a volume of 5 ml and the animals were sacrificed at day 7. One control was treated with saline vehicle (termed saline on the table) and the other had surgery only (surgical control). The statistical analysis based on the data from the double uterine horn model (nonparametric data) was performed on the overall score. The data is rank ordered, a rank value given and an analysis of variance on the ranks is performed. The results are summarized in Tables 16 and 17. HES-1:10 alone or in combination with betamethasone was efficacious at the reduction of adhesions in the rabbit double uterine horn model.

TABLE 16
HES-1:10 + Betamethasone

Treatment		Overall Score
Surgical Control		3+
		3+
		Died
		3+
		3+
5	8.1% RT HES-1:10	2+
		1.5+
		1.5+
		2+
		2+
	8.1% RT HES-1:10 + Betamethasone	0.5+
		1+
		1.5+
		1+
		1+
	8.1% 4C HES-1:10	1+
		1+
		Died
		1.5+
		1.5+
10	8.1% 4C HES-1:10 + Betamethasone	1+
		1.5+

-82-

Treatment	Overall Score
	2+
	2+
	1+
5.4% RT HES-1:10	2+
	1.5+
	1.5+
	1.5+
	1.5+
5.4% RT HES-1:10 + Betamethasone	1.5+
	1.5+
	1+
	2+
	0.5+
5.4% 4C HES-1:10	1.5+
	1+
	Died
	2+
	1+
5 5.4% 4C HES-1:10 + Betamethasone	1.5+
	1+
	2+
	1+
	1.5+

Treatment
Saline

Overall Score

2+

2.5+

2.5+

2+

3+

TABLE 17
% Organ Involvement in Uterine
Horn Adhesion

	Treatment	Right Horn				Left Horn			
		Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right
5	Surgical Control	50	40	30	20	50	40	40	20
		30	40	40	20	30	40	30	20
		DIED							
		30	40	40	30	30	40	30	30
		40	20	20	30	40	20	30	30
	Mean	37.5	28	32.5	25	37.5	28	32.8	25
	8.1% RT HES-1:10	10	40	0	0	10	40	10	0
		10	0	10	10	10	0	10	10
		0	10	20	10	0	10	20	10
		20	20	20	0	20	20	20	0
		10	10	20	10	10	10	10	10
10	Mean	10	16	14	6	16	14	14	6
	8.1% RT HES-1:10 + Betamethasone	0	0	10	0	0	0	10	0
		0	20	20	0	0	20	20	0
		0	10	30	10	0	10	20	10
		0	10	10	0	0	10	10	0+
		30	0	0	0	30	0	20	0
	Mean	6	8	14	2	6	8	16	2
15	8.1% 4C HES-1:10	0	0	10	10	0	0	20	10+
		0	0	20	20	0	0	10	20+

-85-

Treatment	Right Horn				Left Horn			
	Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right
	0	20	20	0	0	20	10	0
	DIED							
	30	0	20	20	30	0	20	20
Mean	7.5	4	17.5	12.5	7.5	4	15	12.5
5	8.1% 4C HES- 1:10 + Betamethasone							
	20	0	10	0	20	0	20	0
	0	10	20	10	0	10	20	10
	10	30	20	0	10	30	10	0
	20	30	20	0	20	30	20	0
	0	10	20	0	0	10	10	0
	Mean	10	16	18	2	10	16	2
	5.4% RT HES- 1:10							
	20	0	20	20	20	20	20	20
	10	20	20	0	10	20	0	0
10	20	0	10	10	20	0	20	10
	0	10	30	20	0	10	10	20
	10	10	10	0	10	10	10	0
	Mean	12	8	18	10	12	12	10
	5.4% RT HES- 1:10 + Betamethasone							
	0	10	30	10	0	10	10	10
	10	0	20	20	0	0	20	20
	0	0	20	10	0	0	10	10
	0	20	20	10	0	20	20	10
	0	0	20	0	0	0	20	0
	Mean	2	6	22	10	0	16	10
	5.4% 4C HES- 1:10							
	0	30	20	0	0	30	20	0
	0	10	20	0	0	10	20	0

DIED

-86-

Treatment	Right Horn				Left Horn			
	Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right
	30	0	20	0	30	0	20	0
	0	10	20	0	0	10	20	0
Mean	7.5	12.5	20	0	7.5	12.5	20	0
5.4% 4C HES- 1:10 + Betamethasone	10	0	20	20	10	0	20	20
	0	0	20	20	0	0	10	20
	0	30	20	0	0	30	20	0
	0	0	10	10	0	0	10	10
	0	10	20	10	0	10	20	10
	0	0	20	20	0	0	10	20
5 Mean	2	8	18	12	2	8	16	12
Saline	20	20	20	20	20	20	20	20
	10	30	20	10	10	30	40	10
	20	40	20	40	20	40	20	40
	20	30	20	0	20	30	30	0
	20	80	30	0	20	80	20	0
Mean	18	40	22	14	15	40	26	145

+ Material present on horns

10 Statistical analysis was performed on the overall
 15 score of the nonparametric data taken from Table 16. The
 data was rank ordered and assigned a rank value. Analysis
 of the variance of the ranks was then performed and the
 resulting student t test results are summarized below.
 Comparison of the rank order of 8.1% RT HES-1:10 with 8.1%
 15 RT HES-1:10 + betamethasone gave a p value of 0.001.

	Treatment	Rank order	p value
	Control	45.0 \pm 0.0	--
	8.1% RT HES- 1:10	29.8 \pm 6.4	0.000
5	8.1% RT HES- 1:10 + betamethasone	9.8 \pm 6.7	0.000
	8.1% 4C HES- 1:10	15.3 \pm 6.8	0.000
10	8.1% 4C HES- 1:10 + betamethasone	21.8 \pm 11.9	0.002
	5.4% RT HES- 1:10	24.6 \pm 5.2	0.000
15	5.4% RT HES- 1:10 + betamethasone	17.8 \pm 11.7	0.000
	5.4% 4C HES- 1:10	18.5 \pm 11.0	0.000
20	5.4% 4C HES- 1:10 + betamethasone	19.2 \pm 9.9	0.000
	Saline	39.6 \pm 4.0	0.017

Example 11: Evaluation of Hetastarch Compositions

25 In this Example, various concentrations of hetastarch
(HES-7-8:10) compositions were evaluated in the rabbit
double uterine horn model for adhesion prevention.
Hetastarch compositions having concentrations of 16.2%,
13.5%, 10.8%, 8.1%, and 5.4% (w/v) (Tables 18 and 18a) were
30 administered in 15 ml and 40.0%, 34.3%, 28.5%, 23.5%,
18.6%, 16.2% and 13.5% (w/v) (Tables 19 and 19a) were
administered in 5 ml at the end of surgery and the animals
were sacrificed at day 7. The surgical control received no
composition. The statistical analysis based on the data
35 from the double uterine horn model (nonparametric data) was

performed on the overall score. The data is rank ordered, a rank value given and an analysis of variance on the ranks is performed. The results are summarized in Tables 18, 18a, 19 and 19a. HES-7-8:10 alone was found to be
5 efficacious at the concentrations tested in reducing adhesions in the rabbit double uterine horn model.

TABLE 18

Treatment		Overall Score
Surgical Control		3+
		3+
		2.5+
		2.5+
		3+
5	16.2% (w/v) Hetastarch	2+
		2+
		2.5+
		2.5+
		2+
13.5% Hetastarch		1.5+
		2+
		1.5+
		1.5+
		1.5+
10.8% Hetastarch		1.5+
		1.5+
		1.5+
		1.5+
		1.5+
8.1% Hetastarch		1.5+
		1.5+
		1.5+
		2+

Treatment

Overall Score

1+

5.4% Hetastarch

2+

1+

1.5+

1.5+

2+

TABLE 18a
% Organ Involvement in Uterine
Horn Adhesion

	Treatment	Right Horn				Left Horn			
		Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right
5	Control	50	60	20	10	50	60	20	10
		20	60	20	20	20	60	20	20
		20	40	10	30	20	40	20	30
		10	30	30	30	10	30	20	30
		20	50	20	20	20	50	20	20
	Mean	24	48	20	22	24	48	20	22
	16.2% (w/v) Hetastarch	30	10	10	10	30	10	10	10
		10	30	30	30	10	30	20	30
		30	30	20	30	30	30	20	30
		30	20	10	10	30	20	20	10+
		50	0	20	0	50	0	20	0
	Mean	30	18	18	16	30	18	18	16
10	13.5% Hetastarch	10	0	30	20	10	0	30	20
		30	20	10	10	30	20	20	10
		20	0	30	10	20	0	20	10
		0	0	10	10	0	0	20	10
		20	10	10	0	20	10	20	0
	Mean	16	6	18	10	16	6	22	10
	10.8% Hetastarch	10	10	10	20	10	10	10	20
		0	10	20	20	0	10	20	20
		0	10	20	10	0	10	10	10+
		0	10	20	20	0	10	20	20
		20	0	20	20	20	0	20	20

Treatment	Right Horn				Left Horn			
	Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right
Mean	6	8	18	18	6	8	16	18
8.1 % Hetastarch	20	0	10	10	20	0	20	10
	10	0	20	20	10	0	20	20
	20	0	10	20	20	0	10	20
	30	0	20	20	30	0	20	20
	0	0	20	0	0	0	20	0
Mean	16	0	16	14	16	0	18	14
5 5.4 % Hetastarch	20	10	20	10	20	10	20	10
	10	0	30	0	10	0	10	0
	20	10	10	20	20	10	10	20
	0	10	20	10	0	10	10	10
	10	30	10	0	10	30	10	0
Mean	12	12	18	8	12	12	12	8

+ Organ with Incision

TABLE 19

Treatment		Overall Adhesion Score
Surgical Control		2.5+
		1.5+
		3+
		3+
		3+
		3+
		2.5+
13.5% Hetastarch		1.5+
		1+
		2+
		2+
		1.5+
		2+
		2+
5 16.2% Hetastarch		1.5+
		2+
		1+
		2+
		1+
		1.5+
		1.5+
18.6% Hetastarch		1.5+
		1.5+
		1.5+

Treatment	Overall Adhesion Score
	1.5+
	1.5+
	1+
	2+
28.5% Hetastarch	1.5+
	1.5+
	1+
	2+
	1.5+
	1.5+
	0.5+
34.3% Hetastarch	2+
	2+
	2+
	2+
	1+
	1+
	1.5+
40% Hetastarch	2+
	1.5+
	1.5+
	2.5+
	2+
	2+

TABLE 19a
% Organ Involvement in Uterine
Horn Adhesion

	Treatment	Right Horn				Left Horn			
		Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right
5	Control	40	40	30	30	40	40	30	30+
		0	20	20	30	0	20	20	30
		30	40	30	20	30	40	30	20
		20	30	30	30	20	30	40	30
		40	20	30	30	40	20	30	30+
		30	40	30	30	30	40	30	30+
		40	20	30	30	40	20	30	30
	Mean	28.6	30	28.6	28.6	28.6	30	28.6	28.6
	13.5% Hetastarch	0	30	20	10	0	30	20	10+
		20	0	30	0	20	0	30	0
		30	20	30	10	30	20	30	10
		30	20	30	0	30	20	20	0
		0	10	20	10	0	10	20	10
		10	20	30	20	10	20	10	20
		30	0	30	20	30	0	20	20
	Mean	17.1	14.3	27.1	10	17.1	14.3	21.4	10
10	16.2% Hetastarch	20	10	20	20	20	0	20	20
		30	0	20	20	30	0	20	20
		0	20	20	0	0	10	20	0
		20	0	30	20	20	0	20	20+
		10	20	20	0	10	20	0	0
		10	0	30	10	10	0	20	10
		0	10	30	30	0	10	30	30
	Mean	12.9	8.6	24.3	14.3	12.9	8.6	18.6	14.3

		Right Horn				Left Horn			
		Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right
	18.6% Hetastarch	20	20	0	20	20	20	20	20+
		0	20	30	10	0	20	20	10
		20	0	30	20	20	0	30	20
		0	10	30	20	0	10	20	20+
		10	0	30	20	10	0	30	20
		50	0	40	40	50	0	40	40
		20	0	20	10	20	0	30	10+
	Mean	17.1	7.1	25.7	20	17.1	7.1	27.1	20
5	23.5% Hetastarch	20	0	30	10	20	0	30	10
		30	20	30	30	30	20	20	30
		10	10	20	20	10	10	30	20+
		20	0	20	20	20	0	20	20
		10	10	30	10	10	10	20	10
		0	0	0	10	0	0	30	0
		20	0	30	20	20	0	30	20
	Mean	15.7	5.7	24.3	15.7	15.7	5.7	25.7	15.7
	Treatment 28.5% Hetastarch	20	0	20	20	20	0	20	20*
		10	20	20	0	10	20	30	0
		0	0	30	30	0	0	30	30*
		20	10	30	20	20	10	20	20
		20	0	20	20	20	0	30	20
		20	0	20	0	20	10	30	0+
		0	0	20	0	0	0	20	0
	Mean	12.9	4.3	22.9	12.9	12.9	5.7	25.7	12.9
10	34.3% Hetastarch	0	20	30	0	0	20	30	0+
		30	20	10	10	30	20	10	10
		40	10	20	0	40	10	10	0

Treatment	Right Horn				Left Horn			
	Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right
	30	20	20	20	30	20	30	20
	0	0	20	20	0	0	30	20
	10	0	30	0	10	0	30	0
	0	30	30	20	0	30	20	20
Mean	15.7	14.3	22.9	10	15.7	14.3	22.9	10
40% Hetastarch	20	10	30	20	20	10	40	20
	20	20	0	30	20	20	0	30+
	0	30	30	10	0	30	30	10
	40	0	20	40	40	0	30	40
	10	30	30	20	10	30	30	20*
	0	20	30	20	0	20	20	20
Mean	15	18.3	23.3	23.3	15	18.3	25	23.3
5 +	Organ with Incision							
*	Material Present on Horns							

Statistical analysis was performed on the overall score of the nonparametric data taken from Tables 18 and 19. The data was rank ordered and assigned a rank value. Analysis of the variance of the ranks was then performed and the resulting student t test results are summarized below.

TABLE 18 ANALYSIS

	Treatment	Rank order	p value
15	Surgical control	27.6 ± 1.71	--
	16.2% Hetastarch	22.2 ± 2.69	0.005
	13.5% Hetastarch	11.6 ± 4.20	0.000
20	10.8% Hetastarch	9.5 ± 0.00	0.000

8.1% Hetastarch	10.0 \pm 5.88	0.000
5.4% Hetastarch	12.1 \pm 7.08	0.001

5

TABLE 19 ANALYSIS

	Group	Rank order	p value
	Control	47.36 \pm 11.91	--
	13.5% Hetastarch	27.71 \pm 12.59	0.011
	16.2% Hetastarch	20.21 \pm 12.56	0.001
10	18.6% Hetastarch	25.71 \pm 11.81	0.005
	23.5% Hetastarch	27.71 \pm 12.59	0.001
	28.5% Hetastarch	16.86 \pm 11.02	0.000
	34.3% Hetastarch	25.79 \pm 14.71	0.011
	40% Hetastarch	33.42 \pm 11.30	0.054

15 Example 12: Evaluation of HES-7-8:10/Lazaroid compositions

In this Example, 16.2%, 13.5%, 10.8%, 8.1% and 5.4% (w/v) hetastarch (HES-7-8:10) alone or in combination with (10.8% and 8.1% (w/v) HES-7-8:10 with 0.6 mg/ml lazaroïd (U-83836E, available from The UpJohn Company, Kalamazoo, MI, USA), were evaluated for adhesion prevention. Lazaroids were found to have a post-surgical anti-adhesion formation effect as disclosed in co-pending U.S. patent application No. 08/341,651, filed November 17, 1994, which is incorporated herein in its entirety. The composition was administered at the end of surgery in a volume of 5 ml and the animals were sacrificed at day 7. The surgical control received no composition. The statistical analysis based on the data from the double uterine horn model (nonparametric data) was performed on the overall score. The data is rank ordered, a rank value given and an analysis of variance on

the ranks is performed. The results are summarized in Tables 20 and 21. HES-7-8:10 alone and in combination with lazaroïd was efficacious at the reduction of adhesions in the rabbit double uterine horn model.

-100-

TABLE 20
Hetastarch + Lazaroid (U-83836E)

Treatment		Overall Score
Surgical Control		3+
		1.5+
		2.5+
		2+
		3+
5	16.2% (w/v) Hetastarch	1.5+
		2+
		1.5+
		2+
		1.5+
	13.5% Hetastarch	1.5+
		2+
		1.5+
		1.5+
		2.5+
	10.8% Hetastarch	2+
		1.5+
		2+
		1.5+
		2+
10	10.8% Hetastarch + lazaroid	1+
		1.5+

-101-

Treatment	Overall Score
	1+
	1.5+
	1.5+
8.1% Hetastarch	1.5+
	1+
	Died
	1.5+
	2+
8.1% Hetastarch + lazaroid	0.5+
	1+
	0.5+
	1+
	0.5+
5.4% Hetastarch	Died
	2+
	1.5+
	1.5+
	2+

TABLE 21
% Organ Involvement in Uterine
Horn Adhesion

	Treatment	Right Horn				Left Horn			
		Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right
5	Control	40	20	30	20	40	20	30	20
		20	0	10	10	20	0	10	10
		40	30	20	30	40	30	20	30+
		20	10	20	20	20	10	20	20+
		30	20	40	20	30	20	40	20
	Mean	30	16	24	20	30	16	24	20
	16.2% (w/v) Hetastarch	20	10	20	10	20	10	20	10
		30	10	20	0	30	10	10	0
		10	20	20	0	10	20	20	0
		10	10	20	10	10	10	20	10
		10	0	20	10	10	0	10	10
	Mean	16	10	20	6	16	10	16	6
10	13.5% Hetastarch	0	20	20	10	0	20	20	10
		20	20	30	20	20	20	30	20+
		0	20	20	10	0	20	20	10
		10	0	10	20	10	0	20	20
		30	10	20	10	30	10	20	10
	Mean	12	14	20	14	12	14	22	14
	10.8% Hetastarch	30	0	20	10	30	0	20	10
		20	0	10	10	20	0	20	10
		10	10	20	10	10	10	20	10
		10	10	10	0	10	10	20	0
		30	10	10	10	30	10	20	10

	Treatment	Right Horn				Left Horn			
		Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right
	Mean	20	6	14	8	20	6	20	8
	10.8% Hetastarch + lazaroid	0	0	20	20	0	0	20	20
		10	0	20	10	10	0	10	10
		0	10	10	0	0	10	10	0
		0	20	10	0	0	20	20	0
		10	0	10	10	10	0	10	10
5	Mean	4	6	14	8	4	6	14	8
	8.1% Hetastarch	10	10	20	0	10	10	10	0
		0	10	20	0	0	10	20	0
						DIED			
		20	0	10	20	20	0	10	20
		20	10	20	30	20	10	20	30+
	Mean	12.5	7.5	17.5	12.5	12.5	7.5	15	12.5
10	8.1% Hetastarch + lazaroid	0	0	10	0	0	0	10	0
		10	0	20	0	10	0	20	0
		0	0	10	0	0	0	10	0
		10	0	20	0	10	0	10	0
		10	0	10	0	10	0	0	0
	Mean	6	0	14	0	6	0	10	0
	5.4% Hetastarch					DIED			
		20	10	20	20	20	10	20	20+
		0	10	20	10	0	10	20	10
		10	0	20	20	10	0	20	20
		30	0	20	10	30	0	20	10
15	Mean	15	5	20	15	15	5	20	15

+ Organ with Incision

Statistical analysis was performed on the overall score of the nonparametric data taken from Table 20. The data was rank ordered and assigned a rank value. Analysis of the variance of the ranks was then performed and the resulting student t test results are summarized below. Comparison of the rank order of 10.8% HES-7-8:10 with 10.8% HES-7-8:10 containing lazaroid gave a p value of 0.011 and comparison of 8.1% HES-7-8:10 with 8.1% HES-7-8:10 containing lazaroid gave a p value of 0.009.

	Treatment	Rank order	p value
	Surgical control	31.3 \pm 7.96	--
5	16.2% Hetastarch	21.7 \pm 6.37	0.068
	13.5% Hetastarch	22.9 \pm 8.06	0.136
	10.8% Hetastarch	24.3 \pm 6.37	0.163
10	10.8% Hetastarch + lazaroid	12.3 \pm 5.14	0.000
	8.1% Hetastarch	17.1 \pm 8.33	0.035
15	8.1% Hetastarch + lazaroid	3.6 \pm 1.96	0.000
	5.4% Hetastarch	23.0 \pm 6.50	0.109
20	5.4% Hetastarch + lazaroid	19.2 \pm 9.9	0.000

Example 13: Evaluation of HES-7-8:10/betamethasone

In this Example, 8.1% (w/v) hetastarch (HES-7-8:10) alone or in combination with 0.005, 0.017, 0.05, 0.17, and 0.5 mg/ml betamethasone sodium phosphate were evaluated for adhesion prevention. Betamethasone (0.017 and 0.17 mg/ml) in saline buffer were used as controls. The surgical controls received no composition. The compositions were administered at the end of surgery in a volume of 10 ml and the animals were sacrificed at day 7. The surgical control received no composition. The statistical analysis based on the data from the double uterine horn model (nonparametric data) was performed on the overall score. The data is rank ordered, a rank value given and an analysis of variance on the ranks is performed. The results are summarized in

Tables 22 and 23. HES-7-8:10 alone and in combination with betamethasone was efficacious at the reduction of adhesions in the rabbit double uterine horn model.

TABLE 22
Hetastarch + Betamethasone

Treatment		Overall Score
	Surgical Control	2.5+
		2.5+
		3+
		2+
		3+
5	8.1% (w/v) Hetastarch	3+
		1.5+
		2+
		1.5+
		1.5+
	8.1% (w/v) Hetastarch + 0.5 mg/ml Betamethasone	1.5+
		1.5+
		1.5+
		1.5+
		1.5+
10	8.1% Hetastarch + 0.17 mg/ml Betamethasone	2+
		1.5+
		1+
		2+
		1+

-108-

	Treatment	Overall Score
	8.1% Hetastarch + 0.05 mg/ml Betamethasone	2+ 1.5+ 1+ 1.5+ 1.5+
5	8.1% Hetastarch + 0.017 mg/ml Betamethasone	1.5+ 2+ 1.5+ 1.5+ 1.5+
	8.1% Hetastarch + 0.005 mg/ml Betamethasone	1.5+ 1.5+ 1.5+ 1.5+
10	0.17 mg/ml Betamethasone	1+ 1+ 2+ 1.5+ 1+
	0.017 mg/ml Betamethasone	1+

Treatment

Overall Score

1.5+

1.5+

2+

1+

TABLE 23
% Organ Involvement in Uterine
Horn Adhesion

	Treatment	Right Horn				Left Horn			
		Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right
5	Control	40	0	30	20	40	0	30	20+
		30	30	20	30	30	30	30	30
		50	20	20	20	50	20	20	20+
		50	20	30	30	50	20	30	30
		20	50	20	30	20	50	20	30
	Mean	38	24	24	26	38	24	26	26
	8.1% (w/v) Hetastarch	50	10	30	20	50	10	30	20+
		0	20	20	20	0	20	10	20
		10	10	30	20	10	10	30	20
		0	10	20	10	0	10	10	10
		10	10	10	0	10	10	10	0
	Mean	14	12	22	14	14	12	18	14
10	8.1% Hetastarch + 0.5 mg/ml betamethasone	10	0	20	10	10	0	10	10
		0	0	20	30	0	0	20	30
		10	0	10	10	10	0	20	10
		20	0	20	0	20	0	30	0
		0	20	10	20	0	20	10	20
	Mean	8	4	18	14	8	4	18	14
15	8.1% Hetastarch + 0.17 mg/ml betamethasone	10	10	10	10	10	10	10	10
		10	0	20	10	10	0	10	10
		0	0	20	20	0	0	20	20

-111-

	Treatment	Right Horn				Left Horn			
		Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right
5		20	10	10	10	20	10	10	10
		0	10	20	0	0	10	20	0*
	Mean	8	6	16	10	8	6	14	10
	8.1% Hetastarch + 0.05 mg/ml betamethasone	20	0	20	20	20	0	20	20
		0	10	20	20	0	10	20	20
		10	0	10	0	10	0	10	0
		0	0	20	30	0	0	30	30
		30	0	10	10	30	0	10	10
	Mean	12	2	16	16	12	2	18	16
	8.1% Hetastarch + 0.017 mg/ml betamethasone	0	10	20	10	0	10	20	10
10		10	10	20	20	10	10	20	20
		0	0	30	20	0	0	30	20
		0	0	20	10	0	0	20	10
		0	20	10	10	0	20	20	10
	Mean	2	8	20	14	2	8	22	14
	8.1% Hetastarch + 0.005 mg/ml betamethasone	0	20	10	10	0	20	10	10
		0	0	20	20	0	0	20	20
15		0	10	20	20	0	10	20	20
		10	0	20	10	10	0	20	10
		10	0	10	10	10	0	20	10
	Mean	4	6	16	14	4	6	18	14
	0.17 mg/ml betamethasone	0	0	20	10	0	0	20	10
		0	0	20	10	0	0	10	10

-112-

Treatment	Right Horn				Left Horn			
	Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right
	20	0	30	10	20	0	20	10
	0	10	10	10	0	10	10	10
	0	10	10	0	0	10	10	0
Mean	4	4	18	8	4	4	14	8
0.017 mg/ml betamethasone	0	0	20	10	0	0	20	10
	0	0	20	20	0	0	20	20
	0	0	20	20	0	0	10	20
	20	20	10	20	20	20	20	20
	0	0	20	10	0	0	10	10
Mean	4	4	18	16	4	4	16	16

5 + Organ with Incision
 * Material Present

Statistical analysis was performed on the overall score of the nonparametric data taken from Table 22. The data was rank ordered and assigned a rank value. Analysis of the variance of the ranks was then performed and the resulting student t test results are summarized below.

	Treatment	Rank order	p value
	Surgical control	41.5 \pm 2.74	--
5	8.1% (w/v) Hetastarch	28.4 \pm 9.96	0.022
	8.1% Hetastarch + 0.5	20.5 \pm 0.00	0.000
10	8.1% Hetastarch + 0.17	20.5 \pm 14.31	0.012
	8.1% Hetastarch + 0.05	20.5 \pm 10.12	0.002
15	8.1% Hetastarch + 0.017	23.7 \pm 6.40	0.000
	8.1% Hetastarch + 0.005	20.5 \pm 0.00	0.000
20	0.17 mg/ml Betamethasone	14.1 \pm 12.8	0.002
	0.017 mg/ml Betamethasone	17.3 \pm 11.97	0.002

25 While the fundamental novel features of the invention has been shown and described, it will be understood that various omissions, substitutions and changes in the form and details illustrated may be made by those skilled in the art without departing from the spirit of the invention. It

30 is the intention, therefore, to be limited only as indicated by the scope of the following claims.

WHAT IS CLAIMED IS:

1. A method for reducing or preventing formation of post-surgical adhesions between tissue surfaces in a body cavity, comprising administering an effective amount of a composition comprising hydroxyethyl starch for a period of time sufficient to permit tissue repair.

2. The method according to claim 1, wherein said tissue repair comprises re-epithelization.

3. The method according to claim 1, wherein said tissue repair comprises mesothelial repair.

4. The method according to claim 1, wherein said hydroxyethyl starch comprises an amylopectin having hydroxyethyl groups which are substituted on a molar ratio ranging between about 0.1 and about 0.8 of a hydroxyethyl group per glucopyranose unit.

5. The method according to claim 4, wherein said hydroxyethyl starch comprises amylopectin monomers of molecular weights ranging between about 3×10^4 and about 4×10^6 daltons.

6. The method according to claim 5, wherein said monomers range between about 2×10^5 and about 2.4×10^6 daltons.

7. The method according to claim 1, wherein said hydroxyethyl starch comprises HES-1:10, HES-7-8:10 or HES-5:10.

8. The method according to claim 1, wherein said composition is administered with a physiologically acceptable vehicle.

9. The method according to claim 8, wherein said vehicle comprises sterile water, saline or aqueous buffer solutions containing alkali or alkaline earth metal carbonates, phosphates, bicarbonates, citrates, borates, acetates, succinates and tromethamine (TRIS).

-115-

10. The method according to claim 8, wherein said vehicle comprises saline, phosphate buffered saline, citrate buffer, and Ringers lactate solution.

11. The method according to claim 1, wherein said
5 composition further comprises an effective amount of at least one pharmaceutically active agent.

12. The method according to claim 11, wherein said pharmaceutically active agent comprises an anti-adhesion formation agent, an antibiotic agent, an antihistaminic, an
10 anti-inflammatory agent, antifungal agent, amoebocidal agent, trichomonacidal agent, antiprotozoal agent, an antiviral agent, antineoplastic agent or anti-inflammatory corticosteroid.

13. The method according to claim 12, wherein said
15 anti-adhesion formation agent comprises a lazareid, a retinoid, quinacrine, manolide or an analog thereof, a 5-lipoxygenase inhibitor, ketotifen or an analog thereof, dipyridamole or an analog thereof, a NSAID, or an anti-inflammatory corticosteroid.

14. The method according to claim 12, wherein said
20 anti-inflammatory corticosteroid comprises betamethasone or dexamethasone.

15. A method for treating a condition requiring an application of a medicament which comprises administering
25 to a body cavity a composition comprising hydroxyethyl starch and at least one pharmaceutically active agent.

16. The method according to claim 15, wherein said hydroxyethyl starch comprises an amylopectin having hydroxyethyl groups which are substituted on a molar ratio
30 ranging between about 0.1 and about 0.8 of a hydroxyethyl group per glucopyranose unit.

17. The method according to claim 16, wherein said hydroxyethyl starch comprises amylopectin monomers of molecular weights ranging between about 3×10^4 and about
35 4×10^6 daltons.

-116-

18. The method according to claim 17, wherein said monomers range between about 2×10^5 and about 2.4×10^6 daltons.

19. The method according to claim 16, wherein said
5 hydroxyethyl starch comprises HES-1:10, HES-7-8:10, or HES-5:10.

20. The method according to claim 16, wherein the composition further comprises a physiologically acceptable vehicle.

10 21. The method according to claim 20, wherein said vehicle comprises sterile water, saline or aqueous buffer solutions containing alkali or alkaline earth metal carbonates, phosphates, bicarbonates, citrates, borates, acetates, succinates and tromethamine (TRIS).

15 22. The method according to claim 20, wherein said vehicle comprises saline, phosphate buffered saline, citrate buffer, and Ringers lactate solution.

23. The method according to claim 16, wherein said
20 pharmaceutically active agent comprises an anti-adhesion formation agent, an antibiotic agent, an antihistaminic, an anti-inflammatory agent, antifungal agent, amoebocidal agent, trichomonacidal agent, antiprotozoal agent, an antiviral agent, antineoplastic agent or anti-inflammatory corticosteroid.

25 24. The method according to claim 23, wherein said anti-adhesion formation agent comprises a lazaroid, a retinoid, quinacrine, manoalide or an analog thereof, a 5-lipoxygenase inhibitor, ketotifen or an analog thereof, dipyridamole or an analog thereof, a NSAID, or an anti-
30 inflammatory corticosteroid.

25. The method according to claim 23, wherein said anti-inflammatory corticosteroid comprises betamethasone or dexamethasone.

26. A method for reducing or preventing formation of
35 adhesions between organ surfaces, comprising administering

-117-

an effective amount of a composition comprising hydroxyethyl starch and an anti-adhesion formation agent for a period of time sufficient to permit tissue repair.

27. The method according to claim 26, wherein said
5 tissue repair comprises re-epithelization.

28. The method according to claim 27, wherein said tissue repair comprises mesothelial repair.

29. The method according to claim 26, wherein said hydroxethyl starch comprises an amylopectin having
10 hydroxyethyl groups which are substituted on a molar ratio ranging between about 0.1 and about 0.8 of a hydroxyethyl group per glucopyranose unit.

30. The method according to claim 29, wherein said hydroxyethyl starch comprises amylopectin monomers of
15 molecular weights ranging between about 3×10^4 and about 4×10^6 daltons.

31. The method according to claim 30, wherein said monomers range between about 2×10^5 and about 2.4×10^6 daltons.

20 32. The method according to claim 29, wherein said hydroxyethyl starch comprises HES-1:10, HES-7-8:10, or HES-5:10.

25 33. The method according to claim 29, wherein said composition further comprises a physiologically acceptable vehicle.

34. The method according to claim 33, wherein said vehicle comprises sterile water, saline or aqueous buffer solutions containing alkali or alkaline earth metal carbonates, phosphates, bicarbonates, citrates, borates,
30 acetates, succinates and tromethamine (TRIS).

35. The method according to claim 33, wherein said vehicle comprises saline, phosphate buffered saline, citrate buffer, and Ringers lactate solution.

36. The method according to claim 26, wherein said
35 anti-adhesion formation agent comprises a lazaroïd, a

-118-

retinoid, quinacrine, manoalide or an analog thereof, a 5-lipoxygenase inhibitor, ketotifen or an analog thereof, dipyrindamole or an analog thereof, a NSAID, or an anti-inflammatory corticosteroid.

5 37. A composition for reducing or preventing post-surgical adhesion formation comprising a pharmaceutically active agent and a hydroxyethyl starch.

 38. The composition according to claim 37, wherein said hydroxyethyl starch comprises an amylopectin having
10 hydroxyethyl groups which are substituted on a molar ratio ranging between about 0.1 and about 0.8 of a hydroxyethyl group per glucopyranose unit.

 39. The composition according to claim 38, wherein said hydroxyethyl starch comprises amylopectin monomers of
15 molecular weights ranging between about 3×10^4 and about 4×10^6 daltons.

 40. The composition according to claim 39, wherein said monomers range between about 2×10^5 and about 2.4×10^6 daltons.

20 41. The composition according to claim 37, wherein said hydroxyethyl starch comprises HES-1:10, HES-7-8:10, or HES-5:10.

 42. The composition according to claim 41, wherein said hydroxyethyl starch is present in an amount ranging
25 between about 0.1% and about 60% (w/v).

 43. The composition according to claim 42, wherein said hydroxyethyl starch is present in an amount ranging between about 5.4% and about 34.3% (w/v).

 44. The composition according to claim 37, wherein
30 said pharmaceutically active agent comprises an anti-adhesion formation agent.

 45. The composition according to claim 44, wherein said anti-adhesion formation agent comprises a lazaroid, a retinoid, quinacrine, manoalide or an analog thereof, a 5-
35 lipoxygenase inhibitor, ketotifen or an analog thereof,

-119-

dipyridamole or an analog thereof, a NSAID, or an anti-inflammatory corticosteroid.

46. The composition according to claim 45, wherein said anti-inflammatory corticosteroid comprises
5 betamethasone or dexamethasone.

47. The composition according to claim 46, wherein said anti-inflammatory corticosteroid is present in an amount ranging between about 0.00001 mg/ml and about 50 mg/ml.

10 48. The composition according to claim 47, wherein said anti-inflammatory agent is present in an amount ranging between about 0.001 mg/ml and about 5 mg/ml.

49. A composition for use in reducing or preventing formation of post-surgical adhesions comprising
15 hydroxyethyl starch.

50. The composition according to claim 49, wherein said hydroxyethyl starch comprises an amylopectin having hydroxyethyl groups which are substituted on a molar ratio ranging between about 0.1 and about 0.8 of a hydroxyethyl
20 group per glucopyranose unit.

51. The composition according to claim 50, wherein said hydroxyethyl starch comprises amylopectin monomers of molecular weights ranging between about 3×10^4 and about 4×10^6 daltons.

25 52. The composition according to claim 51, wherein said monomers range between about 2×10^5 and about 2.4×10^6 daltons.

53. The composition according to claim 49, wherein said hydroxyethyl starch comprises HES-1:10, HES-7-8:10 or
30 HES-5:10.

54. The composition according to claim 49, wherein said composition is administered with a physiologically acceptable vehicle.

55. The composition according to claim 54, wherein
35 said vehicle comprises sterile water, saline or aqueous

-120-

buffer solutions containing alkali or alkaline earth metal carbonates, phosphates, bicarbonates, citrates, borates, acetates, succinates and tromethamine (TRIS).

56. The composition according to claim 54, wherein
5 said vehicle comprises saline, phosphate buffered saline, citrate buffer, and Ringers lactate solution.

57. The composition according to claim 49, wherein said composition further comprises an effective amount of at least one pharmaceutically active agent.

10 58. The composition according to claim 57, wherein said pharmaceutically active agent comprises an anti-adhesion formation agent, an antibiotic agent, an antihistaminic, an anti-inflammatory agent, antifungal agent, amoebocidal agent, trichomonacidal agent,
15 antiprotozoal agent, an antiviral agent, antineoplastic agent or anti-inflammatory corticosteroid.

59. The composition according to claim 58, wherein said anti-adhesion formation agent comprises a lazaroïd, a retinoid, quinacrine, manoalide or an analog thereof, a 5-
20 lipoxxygenase inhibitor, ketotifen or an analog thereof, dipyridamole or an analog thereof, a NSAID, or an anti-inflammatory corticosteroid.

60. The composition according to claim 58, wherein said anti-inflammatory corticosteroid comprises
25 betamethasone or dexamethasone.



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/715	A3	(11) International Publication Number: WO 96/40168 (43) International Publication Date: 19 December 1996 (19.12.96)
(21) International Application Number: PCT/US96/08098 (22) International Filing Date: 31 May 1996 (31.05.96) (30) Priority Data: 08/482,235 7 June 1995 (07.06.95) US (71) Applicant: UNIVERSITY OF SOUTHERN CALIFORNIA [US/US]; University Park Campus, Los Angeles, CA 90089 (US). (72) Inventor: DIZEREGA, Gere, Stodder, 1270 Hillcrest Avenue, Pasadena, CA 91105 (US). (74) Agent: MIAO, Emily; Banner & Allegretti, Ltd., Ten South Wacker Drive, Chicago, IL 60606 (US).		(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the</i> <i>claims and to be republished in the event of the receipt of</i> <i>amendments.</i> (88) Date of publication of the international search report: 23 January 1997 (23.01.97)
(54) Title: USE OF HYDROXYETHYL STARCH TO PREVENT POST SURGICAL ADHESION AND AS AN INTRACAVITY CARRIER DEVICE (57) Abstract Hydroxyethyl starch (HES) and use thereof in methods are provided for reducing or preventing adhesion formation between tissue surfaces, e.g., organ surfaces, in body cavities following surgical procedures and for drug delivery. HES may be used as an absorbable mechanical barrier alone or in combination with one or more anti-adhesion formation compounds for application to injured areas of tissues, e.g., organs, situated in body cavities such as the peritoneal, pelvic, pleural cavity, central nervous system and interligamentous space. HES may also be used as an intracavity carrier device for delivery of pharmaceutically active agents.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 96/08098

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K31/715

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE WPI Week 9403 Derwent Publications Ltd., London, GB; AN 94-022820 XP002018924 & JP,A,05 331 053 (KIBUN FOOD ET AL.) , 14 December 1993 see abstract ---	1,4,5,8
A	EP,A,0 602 585 (FRESENIUS AG) 22 June 1994 ---	
A	EP,A,0 234 897 (ETHICON INC.) 2 September 1987 ---	
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

* & * document member of the same patent family

Date of the actual completion of the international search

20 November 1996

Date of mailing of the international search report

04.12.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Klaver, T

INTERNATIONAL SEARCH REPORT

In International Application No
PCT/US 96/08098

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	TRANSFUSION, vol. 25, no. 3, 1985, pages 230-230-234, XP000609632 R.G. STRAUSS ET AL.: "Effects of hydroxyethyl starch on fibrinogen, fibrin clot formation, and fibrinolysis." ---	
A	J. LAB. CLIN. MED., vol. 108, no. 6, 1986, pages 556-561, XP000609619 M.E. CARR JR.: "Effect of hydroxyethyl starch on the structure of thrombin- and reptilase-induced fibrin gels." cited in the application -----	

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 96/08098

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim(s) 1-36
is(are) directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PATENT US 96/08098

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-602585	22-06-94	DE-A- 4242926	23-06-94
		AU-B- 664927	07-12-95
		AU-A- 5202293	30-06-94
		JP-B- 2540101	02-10-96
		JP-A- 7025788	27-01-95
EP-A-234897	02-09-87	JP-A- 62228021	06-10-87